8-K

WALGREENS BOOTS ALLIANCE, INC.

Date: March 31, 2021

/s/ James Kehoe

Executive Vice President and Global Chief Financial Officer

0001193125-21-101289.txt : 20210331 0001193125-21-101289.hdr.sgml : 20210331 20210331070735 ACCESSION NUMBER: 0001193125-21-101289 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210331 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210331 DATE AS OF CHANGE: 20210331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Walgreens Boots Alliance, Inc. CENTRAL INDEX KEY: 0001618921 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 471758322 STATE OF INCORPORATION: DE FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36759 FILM NUMBER: 21789794 BUSINESS ADDRESS: STREET 1: 108 WILMOT ROAD CITY: DEERFIELD STATE: IL ZIP: 60015 BUSINESS PHONE: (847) 315-2500 MAIL ADDRESS: STREET 1: 108 WILMOT ROAD CITY: DEERFIELD STATE: IL ZIP: 60015 8-K 1 d149076d8k.htm 8-K 8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 31, 2021

WALGREENS BOOTS ALLIANCE, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-36759

47-1758322

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification Number)


108 Wilmot Road, Deerfield, Illinois				60015
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (847) 315-2500

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value	WBA	The Nasdaq Stock Market LLC
3.600% Walgreens Boots Alliance, Inc. notes due 2025	WBA25	The Nasdaq Stock Market LLC
2.125% Walgreens Boots Alliance, Inc. notes due 2026	WBA26	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.

Results of Operations and Financial Condition.

As previously announced on January 6, 2021, Walgreens Boots Alliance, Inc. (the “Company”) entered into a share purchase agreement (the “Share Purchase Agreement”) with AmerisourceBergen Corporation (the “Transaction”). Pursuant to the terms and subject to the conditions set forth in the Share Purchase Agreement, AmerisourceBergen Corporation will purchase the majority of the Company’s Alliance Healthcare business as well as a portion of the Company’s retail pharmacy international businesses in Europe (the “Disposal Group”). The Company will account for the Transaction as a business disposition. The related assets, liabilities and operating results of the Disposal Group will be reported as discontinued operations beginning with the Company’s second quarter fiscal 2021 financial results. As a result of the Transaction, also beginning with the Company’s second quarter fiscal 2021 financial results, the Company has reorganized how its remaining businesses are managed. As such, the Company’s segment reporting structure has been revised to reflect this new structure which is aligned into two reportable segments: United States and International. Historical periods presented with the Company’s second quarter fiscal 2021 financial results will also reflect the Disposal Group as discontinued operations and the Company’s new segment reporting structure.

The unaudited consolidated condensed statements of earnings and certain related financial information for the first quarter of the 2021 fiscal year and for the 2020 and 2019 fiscal years provided in Exhibit 99.1 are derived from the Company’s historical financial statements for the periods presented and have been adjusted to reflect the Disposal Group as discontinued operations and the Company’s new segment structure.

The unaudited consolidated condensed statements of earnings and related financial information provided in Exhibit 99.1 should be read in conjunction with (i) the audited consolidated condensed financial statements, the accompanying notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s Annual Reports on Form 10-K for the years ended August 31, 2020 and 2019 and (ii) the unaudited condensed consolidated financial statements, the accompanying notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s Quarterly Reports on Form 10-Q for the quarterly periods ended November 30, 2020, May 31, 2020, February 28, 2020, November 30, 2019, May 31, 2019, February 28, 2019 and November 30, 2018.

The information in this Item 2.02, including the exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such disclosure in this Form 8-K in such a filing.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits


Exhibit		Description

99.1		Recast of Walgreens Boots Alliance, Inc. dated March 31, 2021

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EX-99.1 2 d149076dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

LOGO

Walgreens Boots Alliance, Inc.

Recast of Prior Periods to Account for Pending Sale of Alliance Healthcare Business

On January 6, 2021, Walgreens Boots Alliance, Inc. (the “Company”) entered into a Share Purchase Agreement (the “Share Purchase Agreement”) with AmerisourceBergen Corporation (the “Transaction”). Pursuant to the terms and subject to the conditions set forth in the Share Purchase Agreement, AmerisourceBergen Corporation will purchase the majority of the Company’s Alliance Healthcare business as well as a portion of the Company’s retail pharmacy international businesses in Europe (the “Disposal Group”). Alliance Healthcare’s investment in China and Italy and its operations in Germany are not part of the Transaction. The Company’s retail pharmacy international operations in The Netherlands, Norway and Lithuania are part of the Transaction. The Transaction is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals. The Company will account for the Transaction as a business disposition. The related assets, liabilities and operating results of the Disposal Group will now be reported as discontinued operations and are reflected as such in the financial results set forth herein for all periods presented. As a result of the Transaction, effective for the financial results for second quarter of fiscal year 2021, the Company has reorganized how remaining businesses are managed. As such, our segment reporting structure has been revised to reflect this new structure and will now be aligned into two reportable segments: United States and International.

United States Segment

The Company’s United States segment includes the Walgreens business which includes the operations of retail drugstores, health and wellness services, and mail and central specialty pharmacy services, and its equity method investment in AmerisourceBergen. Sales for the segment are principally derived from the sale of prescription drugs and a wide assortment of retail products, including health and wellness, beauty, personal care and consumables and general merchandise.

International Segment

The Company’s International segment consists of pharmacy-led health and beauty retail businesses outside the U.S. and pharmaceutical wholesaling and distribution business in Germany. Pharmacy-led health and beauty retail businesses include Boots branded stores in the UK, the Republic of Ireland and Thailand, the Benavides brand in Mexico and the Ahumada brand in Chile. Sales for these businesses are principally derived from the sale of prescription drugs and health and wellness, beauty, personal care and other consumer products.

In addition, corporate-related overhead costs will no longer be allocated to reportable segments in the Company’s financial results and therefore are now reported in the “Corporate and Other” column.

The following tables are provided to present unaudited, recast financial information after considering the impact of the application of discontinued operations and the corresponding revision to our reportable segments.

Certain amounts in the following tables presented may not add due to rounding. Percentages have been calculated using unrounded amounts for all periods presented.

WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES

CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS (RECAST AND UNAUDITED)

(in millions, except per share amounts)



	FISCAL YEAR

	2021			2020														2019

	Q1			Q1			Q2		Q3			Q4			TOTAL			Q1			Q2			Q3			Q4		TOTAL

Sales	$	31,438		$	29,912		$	31,336	$	30,364		$	30,371		$	121,982		$	29,657		$	30,344		$	30,323		$	29,750	$	120,074

Cost of sales		24,808			23,135			24,318		24,406			24,046			95,905			22,495			23,067			23,363			22,989		91,915

Gross profit		6,630			6,777			7,017		5,959			6,324			26,078			7,162			7,277			6,960			6,760		28,159

Selling, general and administrative expenses		5,792			5,869			5,909		7,884			5,773			25,436			5,891			5,834			5,824			6,009		23,557

Equity earnings (loss) in AmerisourceBergen		(1,373	)		13			28		243			57			341			39			83			(16	)		59		164

Operating income (loss)		(535	)		921			1,136		(1,683	)		608			982			1,310			1,526			1,120			810		4,766

Other income (expense)		63			37			28		(32	)		45			77			30			21			184			8		243

Earnings (loss) before interest and tax		(472	)		957			1,164		(1,715	)		653			1,060			1,340			1,547			1,304			818		5,009

Interest expense, net		136			159			156		148			151			613			148			166			173			162		650

Earnings (loss) before tax		(607	)		798			1,008		(1,862	)		502			446			1,191			1,381			1,131			656		4,359

Income tax provision (benefit)		(207	)		23			149		(43	)		210			339			173			240			142			22		577

Post tax earnings (loss) from other equity method investments		15			(13	)		12		6			26			31			11			4			(7	)		—		8

Net earnings (loss) from continuing operations		(385	)		763			870		(1,813	)		318			138			1,029			1,146			982			634		3,790

Net earnings (loss) from discontinued operations		87			79			81		88			39			286			71			(7	)		55			53		172

Net earnings (loss)		(299	)		842			952		(1,726	)		356			424			1,100			1,138			1,037			686		3,962

Net earnings (loss) attributable to noncontrolling interests - continuing operations		5			(6	)		3		(20	)		(19	)		(42	)		(25	)		(20	)		11			8		(26	)

Net earnings attributable to noncontrolling interests - discontinued operations		4			3			2		2			2			9			2			2			1			2		6

Net earnings (loss) attributable to Walgreens Boots Alliance, Inc.	$	(308	)	$	845		$	946	$	(1,708	)	$	373		$	456		$	1,123		$	1,156		$	1,025		$	677	$	3,982


Net earnings (loss) attributable to Walgreens Boots Alliance, Inc.:

Continuing operations	$	(391	)	$	769		$	867	$	(1,794	)	$	337		$	180		$	1,054		$	1,166		$	971		$	626	$	3,816

Discontinued operations		83			76			79		86			36			277			69			(9	)		55			51		166

Total	$	(308	)	$	845		$	946	$	(1,708	)	$	373		$	456		$	1,123		$	1,156		$	1,025		$	677	$	3,982


Basic earnings (loss) per common share:

Continuing operations	$	(0.45	)	$	0.86		$	0.98	$	(2.05	)	$	0.39		$	0.20		$	1.11		$	1.26		$	1.07		$	0.70	$	4.14

Discontinued operations		0.10			0.08			0.09		0.10			0.04			0.31			0.07			(0.01	)		0.06			0.06		0.18

Total	$	(0.36	)	$	0.95		$	1.07	$	(1.95	)	$	0.43		$	0.52		$	1.18		$	1.25		$	1.13		$	0.75	$	4.32

Diluted earnings (loss) per common share:

Continuing operations	$	(0.45	)	$	0.86		$	0.98	$	(2.05	)	$	0.39		$	0.20		$	1.11		$	1.25		$	1.07		$	0.69	$	4.13

Discontinued operations		0.10			0.08			0.09		0.10			0.04			0.31			0.07			(0.01	)		0.06			0.06		0.18

Total	$	(0.36	)	$	0.95		$	1.07	$	(1.95	)	$	0.43		$	0.52		$	1.18		$	1.24		$	1.13		$	0.75	$	4.31

Weighted average common shares outstanding:

Basic		865.3			891.4			884.5		875.4			866.5			879.4			948.2			928.4			909.9			899.6		921.5

Diluted		865.3			892.6			885.5		875.4			867.1			880.3			951.4			930.7			911.2			900.7		923.5

WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES

SUPPLEMENTAL INFORMATION (RECAST AND UNAUDITED)

REGARDING NON-GAAP FINANCIAL MEASURES

(in millions, except per share amounts)

The following information provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this press release to the most directly comparable financial measures calculated and presented in accordance with generally accepted accounting principles in the United States (GAAP). The Company has provided the non-GAAP financial measures in the press release, which are not calculated or presented in accordance with GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with GAAP. Please refer to the notes to the “Net Earnings and Diluted Net Earnings (Loss) Per Share - Continuing Operations” reconciliation table below for definitions of non-GAAP financial measures and related adjustments presented in this press release.

These supplemental non-GAAP financial measures are presented because the Company’s management has evaluated its financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the supplemental non-GAAP financial measures presented provide additional perspective and insights when analyzing the core operating performance of the Company’s business from period to period and trends in the Company’s historical operating results. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented in the press release.

NET EARNINGS (LOSS) AND DILUTED NET EARNINGS (LOSS) PER SHARE



	FISCAL YEAR

	2021			2020															2019

	Q1			Q1			Q2			Q3			Q4			TOTAL			Q1			Q2			Q3			Q4			TOTAL


Net earnings (loss) attributable to Walgreens Boots Alliance, Inc. - continuing operations (GAAP)	$	(391	)	$	769		$	867		$	(1,794	)	$	337		$	180		$	1,054		$	1,166		$	971		$	626		$	3,816

Adjustments to operating income (loss):

Adjustments to equity earnings (loss) in AmerisourceBergen¹		1,481			80			73			(105	)		49			97			44			9			137			42			233

Acquisition-related amortization²		95			99			98			94			94			384			103			103			107			102			416

Transformational cost management³		100			79			118			310			212			719			29			55			67			176			327

LIFO provision⁴		33			33			28			29			6			95			39			8			29			60			136

Acquisition-related costs⁵		21			124			99			68			24			315			66			82			80			75			303

Store optimization³		—			9			30			10			5			53			20			31			49			97			196

Impairment of goodwill and intangible assets⁶		—			—			—			2,001			15			2,016			—			—			—			73			73

Store damage and inventory losses⁷		—			—			—			75			(7	)		68			—			—			—			—			—

Certain legal and regulatory accruals and settlements⁸		—			—			—			—			—			—			10			14			7			—			31

Total adjustments to operating income (loss)		1,731			424			445			2,481			398			3,747			311			303			476			625			1,715



Adjustments to other income (expense):

Net investment hedging (gain) loss⁹		9			(11	)		7			(2	)		(4	)		(11	)		(3	)		6			8			8			18

Gain on sale of equity method investment¹⁰		—			(1	)		—			—			—			(1	)		—			—			—			—			—

Impairment of equity method investment¹¹		—			—			—			71			—			71			—			—			—			—			—

Termination of option granted to Rite Aid¹²		—			—			—			—			—			—			—			—			(173	)		—			(173	)

Total adjustments to other income (expense)		9			(12	)		6			69			(4	)		59			(3	)		6			(165	)		8			(155	)



Adjustments to income tax provision:

U.S. tax law changes¹³		—			(6	)		—			—			—			(6	)		(12	)		9			—			(5	)		(8	)

UK tax rate changes¹³		—			—			—			—			139			139			—			—			—			—			—

Tax impact of adjustments¹³		(61	)		(80	)		(90	)		(180	)		(84	)		(433	)		(54	)		(63	)		(48	)		(92	)		(257	)

Equity method non-cash tax¹³		(346	)		(2	)		1			53			8			60			4			15			(10	)		9			18

Total adjustments to income tax provision		(407	)		(88	)		(89	)		(127	)		64			(240	)		(62	)		(39	)		(58	)		(88	)		(247	)

NET EARNINGS (LOSS) AND DILUTED NET EARNINGS (LOSS) PER SHARE



	FISCAL YEAR

	2021			2020															2019

	Q1			Q1			Q2			Q3			Q4			TOTAL			Q1			Q2			Q3			Q4			TOTAL


Adjustments to equity earnings in other equity method investments¹⁴		13			28			15			3			8			54			—			—			23			17			40



Adjustments to net earnings (loss) attributable to noncontrolling interests:

Impairment of goodwill and intangible assets⁶		—			—			—			(14	)		—			(14	)		—			—			—			—			—
Transformational cost management³		—			—			—			—			(10	)		(10	)		—			—			—			—			—

Acquisition-related amortization²		(4	)		—			—			—			(4	)		(4	)		—			—			—			—			—
LIFO provision⁴		(3	)		—			—			—			(1	)		(1	)		—			—			—			—			—

Total adjustments to net earnings (loss) attributable to noncontrolling interests - continuing		(8	)		—			—			(14	)		(15	)		(29	)		—			—			—			—			—



Adjusted net earnings attributable to Walgreens Boots Alliance, Inc. - continuing operations (Non-GAAP measure)	$	947		$	1,121		$	1,246		$	618		$	786		$	3,772		$	1,300		$	1,435		$	1,247		$	1,187		$	5,169



Net earnings (loss) attributable to Walgreens Boots Alliance, Inc. - discontinued operations (GAAP)	$	83		$	76		$	79		$	86		$	36		$	277		$	69		$	(9	)	$	55		$	51		$	166
Acquisition-related amortization²		21			19			19			19			19			76			20			20			20			19			78

Transformational cost management³		4			6			5			4			58			73			1			95			19			36			151
Acquisition-related costs⁵		2			—			—			—			1			1			—			—			—			—			—

Equity method non-cash tax¹³		—			—			—			—			—			—			—			(5	)		(7	)		—			(12	)
Tax impact of adjustments¹³		(5	)		—			(7	)		(4	)		(14	)		(25	)		(4	)		(13	)		5			(10	)		(22	)

Total adjustments to net earnings (loss) attributable to Walgreens Boots Alliance, Inc. - discontinued operations		22			25			17			19			64			125			17			97			37			45			195



Adjusted net earnings attributable to Walgreens Boots Alliance, Inc. - discontinued operations (Non-GAAP measure)	$	105		$	101		$	97		$	105		$	100		$	403		$	86		$	87		$	91		$	97		$	360




Adjusted net earnings attributable to Walgreens Boots Alliance, Inc. (Non-GAAP measure)		1,052			1,222			1,343			723			887			4,175			1,386			1,522			1,338			1,284			5,529



Diluted net earnings (loss) per common share - continuing operations (GAAP)¹⁵	$	(0.45	)	$	0.86		$	0.98		$	(2.05	)	$	0.39		$	0.20		$	1.11		$	1.25		$	1.07		$	0.69		$	4.13
Adjustments to operating income (loss)		2.00			0.47			0.50			2.83			0.46			4.26			0.33			0.33			0.52			0.69			1.86

Adjustments to other income (expense)		0.01			(0.01	)		0.01			0.08			—			0.07			—			0.01			(0.18	)		0.01			(0.17	)
Adjustments to income tax provision		(0.47	)		(0.10	)		(0.10	)		(0.14	)		0.07			(0.27	)		(0.07	)		(0.04	)		(0.06	)		(0.10	)		(0.27	)

Adjustments to equity earnings in other equity method investments¹⁴		0.01			0.03			0.02			—			0.01			0.06			—			—			0.02			0.02			0.04

Adjustments to net earnings (loss) attributable to noncontrolling interests		(0.01	)		—			—			(0.02	)		(0.02	)		(0.03	)		—			—			—			—			—
Adjusted diluted net earnings per common share - continuing operations (Non-GAAP measure)¹⁶	$	1.09		$	1.26		$	1.41		$	0.71		$	0.91		$	4.28		$	1.37		$	1.54		$	1.37		$	1.32		$	5.60



Diluted net earnings (loss) per common share - discontinued operations (GAAP)¹⁵	$	0.10		$	0.08		$	0.09		$	0.10		$	0.04		$	0.31		$	0.07		$	(0.01	)	$	0.06		$	0.06		$	0.18
Total adjustments to net earnings (loss) attributable to Walgreens Boots Alliance, Inc. – discontinued operations		0.03			0.03			0.02			0.02			0.07			0.14			0.02			0.10			0.04			0.05			0.21

Adjusted diluted net earnings per common share - discontinued operations (Non-GAAP measure)¹⁶	$	0.12		$	0.11		$	0.11		$	0.12		$	0.12		$	0.46		$	0.09		$	0.09		$	0.10		$	0.11		$	0.39



Adjusted diluted net earnings per common share (Non-GAAP measure)	$	1.22		$	1.37		$	1.52		$	0.83		$	1.02		$	4.74		$	1.46		$	1.64		$	1.47		$	1.43		$	5.99

NET EARNINGS (LOSS) AND DILUTED NET EARNINGS (LOSS) PER SHARE

Adjustments to equity earnings (loss) in AmerisourceBergen consist of the Company’s proportionate share of non-GAAP adjustments reported by AmerisourceBergen consistent with the Company’s non-GAAP measures. The Company recognized equity losses in AmerisourceBergen of $1,373 million during the three months ended November 30, 2020. These equity losses are primarily due to AmerisourceBergen recognition of $5.6 billion, net of tax, charges related to its ongoing opioid litigation in its financial statements for the three months period ended September 30, 2020.

Acquisition related amortization includes amortization of acquisition-related intangible assets and inventory valuation adjustments. Amortization of acquisition-related intangible assets includes amortization of intangible assets such as customer relationships, trade names, trademarks and contract intangibles. Intangible asset amortization excluded from the related non-GAAP measure represents the entire amount recorded within the Company’s GAAP financial statements, the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP measures. Amortization expense, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised. These charges are primarily recorded within selling, general and administrative expenses. Business combination accounting principles require us to measure acquired inventory at fair value. The fair value of the inventory reflects cost of acquired inventory and a portion of the expected profit margin. The acquisition-related inventory valuation adjustments excludes the expected profit margin component from cost of sales recorded under the business combination accounting principles.

Transformational Cost Management Program and Store Optimization Program charges are costs associated with a formal restructuring plan. These charges are primarily recorded within selling, general and administrative expenses. These costs do not reflect current operating performance and are impacted by the timing of restructuring activity.

⁴

The Company’s United States segment inventory is accounted for using the last-in-first-out (“LIFO”) method. This adjustment represents the impact on cost of sales as if the United States segment inventory is accounted for using the first-in first-out (“FIFO”) method. The LIFO provision is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and other external influences. Therefore, the Company cannot control the amounts recognized or timing of these items.

⁵

Acquisition related costs are transaction and integration costs associated with certain merger, acquisition and divestitures related activities. These costs include all charges incurred on certain merger, acquisition and divestitures related activities, for example, this includes costs related to integration efforts for successful merger, acquisition and divestitures activities. These charges are primarily recorded within selling, general and administrative expenses. These costs are significantly impacted by the timing and complexity of the underlying merger and acquisition related activities and do not reflect the Company’s current operating performance.

⁶

Consist of impairment charges recognized in relation to goodwill and intangible assets. These charges are recorded primarily within selling, general and administrative expenses. These charges are inconsistent in size and are significantly impacted by the performance and valuation of the Company’s reporting units and intangible assets. The Company recognized goodwill and intangible asset impairment charges of $2.0 billion in the Boots reporting unit during the three months ended May 31, 2020.

⁷	Store damage and inventory losses as a result of looting in the U.S., net of insurance recoveries.

⁸

Certain legal and regulatory accruals and settlements relate to significant charges associated with certain legal proceedings. The Company excludes these charges when evaluating operating performance because it does not incur such charges on a predictable basis and exclusion of such charges enables more consistent evaluation of the Company’s operating performance. These charges are recorded within selling, general and administrative expenses.

⁹

Gain or loss on certain derivative instruments used as economic hedges of the Company’s net investments in foreign subsidiaries. These charges are recorded within other income (expense). We do not believe this volatility related to mark-to-market adjustment on the underlying derivative instruments reflects the Company’s operational performance.

¹⁰	Includes significant gain on sale of equity method investment and related adjustments.

¹¹	Consists of Impairment charges recognized in relation to the Company’s equity method investment in China. These are recorded in other income (expense).

¹²	The option granted to Rite Aid to become a member of the Company’s group purchasing organization was terminated during fiscal 2019, resulting in recognition of a gain in other income (expense).

¹³

Adjustments to income tax provision include adjustments to the GAAP basis tax provision commensurate with non-GAAP adjustments and certain discrete tax items including U.S. tax law changes, a UK tax rate change and equity method non-cash tax. These charges are recorded within income tax provision (benefit).

¹⁴

Adjustments to post tax equity earnings from other equity method investments consist of the proportionate share of certain equity method investees’ non-cash items or unusual or infrequent items consistent with the Company’s non-GAAP adjustments. These charges are recorded within post tax earnings (loss) from other equity method investments. Although the Company may have shareholder rights and board representation commensurate with its ownership interests in these equity method investees, adjustments relating to equity method investments are not intended to imply that the Company has direct control over their operations and resulting revenue and expenses. Moreover, these non-GAAP financial measures have limitations in that they do not reflect all revenue and expenses of these equity method investees.

¹⁵

Due to the anti-dilutive effect resulting from the reported net loss, the impact of potentially dilutive securities on the per share amounts has been omitted from the quarterly calculation of weighted-average common shares outstanding for diluted earnings per share for the three months ended November 30, 2020 and May 30, 2020.

¹⁶	Includes impact of potentially dilutive securities in the quarterly calculation of weighted-average common shares, diluted for adjusted diluted net earnings per common share calculation purposes for the three months ended November 30, 2020 and May 30, 2020.

NET EARNINGS (LOSS) - RECONCILIATION TO AMOUNTS PREVIOUSLY REPORTED


	FISCAL YEAR 2020									FISCAL YEAR 2019
	WBA (as previously reported)			Discontinued Operations			WBA continuing operations (as recast)			WBA (as previously reported)			Discontinued Operations			WBA continuing operations (as recast)

Net earnings attributable to Walgreens Boots Alliance, Inc. (GAAP)	$	456		$	277		$	180		$	3,982		$	166		$	3,816


Adjustments to operating income (loss):

Adjustments to equity earnings (loss) in AmerisourceBergen		97			—			97			233			—			233

Acquisition-related amortization		460			76			384			494			78			416

Transformational cost management		792			73			719			477			151			327

LIFO provision		95			—			95			136			—			136

Acquisition-related costs		316			1			315			303			—			303

Store optimization		53			—			53			196			—			196

Impairment of goodwill and intangible assets		2,016			—			2,016			73			—			73

Store damage and inventory losses		68			—			68			—			—			—

Certain legal and regulatory accruals and settlements		—			—			—			31			—			31

Total adjustments to operating income (loss)		3,898			150			3,747			1,944			229			1,715


Adjustments to other income (expense):

Net investment hedging (gain) loss		(11	)		—			(11	)		18			—			18

Gain on sale of equity method investment		(1	)		—			(1	)		—			—			—

Impairment of equity method investment		71			—			71			—			—			—

Termination of option granted to Rite Aid		—			—			—			(173	)		—			(173	)

Total adjustments to other income (expense)		59			—			59			(155	)		—			(155	)


Adjustments to income tax provision:

U.S. tax law changes		(6	)		—			(6	)		(8	)		—			(8	)

UK tax rate changes		139			—			139			—			—			—

Tax impact of adjustments		(458	)		(25	)		(433	)		(291	)		(34	)		(257	)

Equity method non-cash tax		60			—			60			18			—			18

Total adjustments to income tax provision		(264	)		(25	)		(240	)		(281	)		(34	)		(247	)


Adjustments to equity earnings in other equity method investments		54			—			54			40			—			40


Adjustments to net earnings (loss) attributable to noncontrolling interests:

Impairment of goodwill and intangible assets		(14	)		—			(14	)		—			—			—

Transformational cost management		(10	)		—			(10	)		—			—			—

Acquisition-related amortization		(4	)		—			(4	)		—			—			—

LIFO provision		(1	)		—			(1	)		—			—			—

Total adjustments to net earnings (loss) attributable to noncontrolling interests		(29	)		—			(29	)		—			—			—

Adjusted net earnings attributable to Walgreens Boots Alliance, Inc. (Non-GAAP measure)	$	4,174		$	402		$	3,772		$	5,530		$	360		$	5,169

GAAP TO NON-GAAP RECONCILIATION - RECONCILING AMOUNTS PREVIOUSLY REPORTED


	FISCAL YEAR 2020									FISCAL YEAR 2019
	WBA (as previously reported)			Discontinued Operations			WBA continuing operations (as recast)			WBA (as previously reported)			Discontinued Operations			WBA continuing operations (as recast)

Sales	$	139,537		$	19,349		$	121,982		$	136,866		$	18,618		$	120,074

Gross profit (GAAP)	$	28,017		$	1,940		$	26,078		$	30,076		$	1,917		$	28,159

Transformational cost management		5			—			5			45			—			45

LIFO provision		95			—			95			136			—			136

Acquisition-related costs		67			—			67			63			—			63

Store damages and inventory losses		54			—			54			—			—			—

Store optimization		1			—			1			8			—			8

Adjusted gross profit (Non-GAAP measure)	$	28,240		$	1,940		$	26,301		$	30,328		$	1,917		$	28,411


Selling, general and administrative expenses (GAAP)	$	27,045		$	1,610		$	25,436		$	25,242		$	1,685		$	23,557

Impairment of goodwill and intangible assets		(2,016	)		—			(2,016	)		(73	)		—			(73	)

Acquisition-related amortization		(460	)		(76	)		(384	)		(493	)		(78	)		(416	)

Transformational cost management		(787	)		(73	)		(714	)		(433	)		(151	)		(282	)

Acquisition-related costs		(249	)		(1	)		(248	)		(241	)		—			(240	)

Store damages and inventory losses		(13	)		—			(13	)		—			—			—

Store optimization		(52	)		—			(52	)		(189	)		—			(189	)

Certain legal and regulatory accruals and settlements		—			—			—			(31	)		—			(31	)

Adjusted selling, general and administrative expenses (Non-GAAP measure)	$	23,467		$	1,459		$	22,008		$	23,783		$	1,456		$	22,326


Operating income (GAAP)	$	1,312		$	330		$	982		$	4,998		$	232		$	4,766

Impairment of goodwill and intangible assets		2,016			—			2,016			73			—			73

Adjustments to equity earnings in AmerisourceBergen		97			—			97			233			—			233

Acquisition-related amortization		460			76			384			494			78			416

Transformational cost management		792			73			719			477			151			327

LIFO provision		95			—			95			136			—			136

Acquisition-related costs		316			1			315			303			—			303

Store damages and inventory losses		68			—			68			—			—			—

Store optimization		53			—			53			196			—			196

Certain legal and regulatory accruals and settlements		—			—			—			31			—			31

Adjusted operating income (Non-GAAP measure)	$	5,211		$	481		$	4,730		$	6,942		$	461		$	6,481


Gross margin (GAAP)		20.1	%		10.0	%		21.4	%		22.0	%		10.3	%		23.5	%

Adjusted gross margin (Non-GAAP measure)		20.2	%		10.0	%		21.6	%		22.2	%		10.3	%		23.7	%

Selling, general and administrative expenses percent to sales (GAAP)		19.4	%		8.3	%		20.9	%		18.4	%		9.1	%		19.6	%

Adjusted selling, general and administrative expenses percent to sales (Non-GAAP measure)		16.8	%		7.5	%		18.0	%		17.4	%		7.8	%		18.6	%

Operating margin (GAAP)¹		0.7	%		1.7	%		0.5	%		3.5	%		1.2	%		3.8	%

Adjusted operating margin (Non-GAAP measure)¹		3.4	%		2.5	%		3.5	%		4.8	%		2.5	%		5.1	%

¹ Operating margins and adjusted operating margins have been calculated excluding equity earnings (loss) in AmerisourceBergen and adjusted equity earnings (loss) in AmerisourceBergen, respectively.

SEGMENT RECONCILIATION GAAP TO NON-GAAP



	FISCAL YEAR 2021

	Three months ended November 30, 2020 (Q1)

	United States			International			Corporate and Other²			Walgreens Boots Alliance, Inc.

Sales	$	27,163		$	4,285		$	(10	)	$	31,438

Gross profit (GAAP)	$	5,639		$	990		$	1		$	6,630

Transformational cost management		(1	)		—			—			(1	)

LIFO provision		33			—			—			33


Adjusted gross profit (Non-GAAP measure)	$	5,671		$	990		$	1		$	6,662



Selling, general and administrative expenses (GAAP)	$	4,770		$	952		$	70		$	5,792

Acquisition-related amortization		(76	)		(19	)		—			(95	)

Transformational cost management		(61	)		(27	)		(12	)		(100	)

Acquisition-related costs		(8	)		(2	)		(12	)		(21	)


Adjusted selling, general and administrative expenses (Non-GAAP measure)	$	4,625		$	904		$	46		$	5,574


Operating income (loss) (GAAP)	$	(504	)	$	39		$	(69	)	$	(535	)

Adjustments to equity earnings in AmerisourceBergen		1,481			—			—			1,481

Acquisition-related amortization		76			19			—			95

Transformational cost management		60			27			12			100

LIFO provision		33			—			—			33

Acquisition-related costs		8			2			12			21


Adjusted operating income (loss) (Non-GAAP measure)	$	1,155		$	87		$	(45	)	$	1,196



Gross margin (GAAP)		20.8	%		23.1	%					21.1	%

Adjusted gross margin (Non-GAAP measure)		20.9	%		23.1	%					21.2	%

Selling, general and administrative expenses percent to sales (GAAP)		17.6	%		22.2	%					18.4	%

Adjusted selling, general and administrative expenses percent to sales (Non-GAAP measure)		17.0	%		21.1	%					17.7	%

Operating margin (GAAP)¹		3.2	%		0.9	%					2.7	%

Adjusted operating margin (Non-GAAP measure)¹		3.9	%		2.0	%					3.5	%

¹ Operating margins and adjusted operating margins have been calculated excluding equity earnings (loss) in AmerisourceBergen and adjusted equity earnings (loss) in AmerisourceBergen, respectively.

² Includes certain eliminations

SEGMENT RECONCILIATION GAAP TO NON-GAAP



	Fiscal year ended August 31, 2020												Fiscal year ended August 31, 2019

	United States			International			Corporate and Other			Walgreens Boots Alliance, Inc.			United States			International			Corporate and Other			Walgreens Boots Alliance, Inc.

Sales	$	107,701		$	14,281		$	—		$	121,982		$	104,532		$	15,542		$	—		$	120,074

Gross profit (GAAP)	$	22,302		$	3,774		$	2		$	26,078		$	23,618		$	4,540		$	2		$	28,159

Transformational cost management		3			2			—			5			—			45			—			45

LIFO provision		95			—			—			95			136			—			—			136

Acquisition-related costs		67			—			—			67			63			—			—			63

Store damages and inventory losses		54			—			—			54			—			—			—			—

Store optimization		1			—			—			1			8			—			—			8


Adjusted gross profit (Non-GAAP measure)	$	22,523		$	3,776		$	2		$	26,301		$	23,825		$	4,584		$	2		$	28,411



Selling, general and administrative expenses (GAAP)	$	19,331		$	5,863		$	241		$	25,436		$	19,307		$	4,091		$	158		$	23,557

Impairment of goodwill and intangible assets		(32	)		(1,984	)		—			(2,016	)		—			(73	)		—			(73	)

Acquisition-related amortization		(309	)		(75	)		—			(384	)		(315	)		(101	)		—			(416	)

Transformational cost management		(495	)		(179	)		(40	)		(714	)		(188	)		(93	)		(1	)		(282	)

Acquisition-related costs		(229	)		(6	)		(12	)		(248	)		(236	)		—			(5	)		(240	)

Store damages and inventory losses		(13	)		—			—			(13	)		—			—			—			—

Store optimization		(52	)		—			—			(52	)		(189	)		—			—			(189	)

Certain legal and regulatory accruals and settlements		—			—			—			—			(31	)		—			—			(31	)


Adjusted selling, general and administrative expenses (Non-GAAP measure)	$	18,199		$	3,619		$	189		$	22,008		$	18,348		$	3,825		$	153		$	22,326



Operating income (loss) (GAAP)	$	3,312		$	(2,090	)	$	(239	)	$	982		$	4,475		$	448		$	(157	)	$	4,766

Impairment of goodwill and intangible assets		32			1,984			—			2,016			—			73			—			73

Adjustments to equity earnings in AmerisourceBergen		97			—			—			97			233			—			—			233

Acquisition-related amortization		309			75			—			384			315			101			—			416

Transformational cost management		498			182			40			719			189			137			1			327

LIFO provision		95			—			—			95			136			—			—			136

Acquisition-related costs		296			6			12			315			299			—			5			303

Store damages and inventory losses		68			—			—			68			—			—			—			—

Store optimization		53			—			—			53			196			—			—			196

Certain legal and regulatory accruals and settlements		—			—			—			—			31			—			—			31


Adjusted operating income (loss) (Non-GAAP measure)	$	4,761		$	157		$	(187	)	$	4,730		$	5,873		$	759		$	(152	)	$	6,481




Gross margin (GAAP)		20.7	%		26.4	%					21.4	%		22.6	%		29.2	%					23.5	%

Adjusted gross margin (Non-GAAP measure)		20.9	%		26.4	%					21.6	%		22.8	%		29.5	%					23.7	%

Selling, general and administrative expenses percent to sales (GAAP)		17.9	%		41.1	%					20.9	%		18.5	%		26.3	%					19.6	%

Adjusted selling, general and administrative expenses percent to sales (Non-GAAP measure)		16.9	%		25.3	%					18.0	%		17.6	%		24.6	%					18.6	%

Operating margin (GAAP)¹		2.8	%		(14.6	)%					0.5	%		4.1	%		2.9	%					3.8	%

Adjusted operating margin (Non-GAAP measure)¹		4.0	%		1.1	%					3.5	%		5.2	%		4.9	%					5.1	%

¹ Operating margins and adjusted operating margins have been calculated excluding equity earnings (loss) in AmerisourceBergen and adjusted equity earnings (loss) in AmerisourceBergen, respectively.

SEGMENT RECONCILIATION GAAP TO NON-GAAP


	FISCAL YEAR 2020
	Three months ended November 30, 2019 (Q1)												Three months ended February 29, 2020 (Q2)
	United States			International			Corporate and Other			Walgreens Boots Alliance, Inc.			United States			International			Corporate and Other			Walgreens Boots Alliance, Inc.

Sales	$	26,133		$	3,779		$	—		$	29,912		$	27,245		$	4,091		$	—		$	31,336

Gross profit (GAAP)	$	5,714		$	1,064		$	(1	)	$	6,777		$	5,827		$	1,188		$	3		$	7,017

Transformational cost management		—			3			—			3			3			—			—			3

LIFO provision		33			—			—			33			28			—			—			28

Acquisition-related costs		28			—			—			28			32			—			—			32

Store optimization		—			—			—			—			1			—			—			1


Adjusted gross profit (Non-GAAP measure)	$	5,776		$	1,066		$	(1	)	$	6,842		$	5,890		$	1,188		$	3		$	7,081


Selling, general and administrative expenses (GAAP)	$	4,809		$	1,012		$	48		$	5,869		$	4,796		$	1,048		$	65		$	5,909

Acquisition-related amortization		(77	)		(22	)		—			(99	)		(79	)		(19	)		—			(98	)

Transformational cost management		(65	)		(10	)		(2	)		(77	)		(53	)		(44	)		(18	)		(115	)

Acquisition-related costs		(94	)		(1	)		—			(95	)		(66	)		—			(1	)		(67	)

Store optimization		(8	)		—			—			(8	)		(29	)		—			—			(29	)


Adjusted selling, general and administrative expenses (Non-GAAP measure)	$	4,565		$	979		$	46		$	5,589		$	4,569		$	985		$	45		$	5,600


Operating income (loss) (GAAP)	$	918		$	52		$	(48	)	$	921		$	1,059		$	140		$	(62	)	$	1,136

Adjustments to equity earnings in AmerisourceBergen		80			—			—			80			73			—			—			73

Acquisition-related amortization		77			22			—			99			79			19			—			98

Transformational cost management		65			13			2			79			56			44			18			118

LIFO provision		33			—			—			33			28			—			—			28

Acquisition-related costs		122			1			—			124			98			—			1			99

Store optimization		9			—			—			9			30			—			—			30


Adjusted operating income (loss) (Non-GAAP measure)	$	1,304		$	87		$	(46	)	$	1,345		$	1,422		$	203		$	(43	)	$	1,582



Gross margin (GAAP)		21.9	%		28.2	%					22.7	%		21.4	%		29.0	%					22.4	%

Adjusted gross margin (Non-GAAP measure)		22.1	%		28.2	%					22.9	%		21.6	%		29.0	%					22.6	%

Selling, general and administrative expenses percent to sales (GAAP)		18.4	%		26.8	%					19.6	%		17.6	%		25.6	%					18.9	%

Adjusted selling, general and administrative expenses percent to sales (Non-GAAP measure)		17.5	%		25.9	%					18.7	%		16.8	%		24.1	%					17.9	%

Operating margin (GAAP)¹		3.5	%		1.4	%					3.0	%		3.8	%		3.4	%					3.5	%

Adjusted operating margin (Non-GAAP measure)¹		4.6	%		2.3	%					4.2	%		4.8	%		5.0	%					4.7	%

¹ Operating margins and adjusted operating margins have been calculated excluding equity earnings (loss) in AmerisourceBergen and adjusted equity earnings (loss) in AmerisourceBergen, respectively.

SEGMENT RECONCILIATION GAAP TO NON-GAAP


	FISCAL YEAR 2020
	Three months ended May 31, 2020 (Q3)												Three months ended August 31, 2020 (Q4)
	United States			International			Corporate and Other			Walgreens Boots Alliance, Inc.			United States			International			Corporate and Other			Walgreens Boots Alliance, Inc.

Sales	$	27,357		$	3,008		$	—		$	30,364		$	26,967		$	3,403		$	—		$	30,371

Gross profit (GAAP)	$	5,275		$	684		$	—		$	5,959		$	5,486		$	838		$	—		$	6,324

Transformational cost management		—			1			—			1			(1	)		(1	)		—			(2	)

LIFO provision		29			—			—			29			6			—			—			6

Acquisition-related costs		7			—			—			7			—			—			—			—

Store damages and inventory losses		60			—			—			60			(6	)		—			—			(6	)

Store optimization		—			—			—			—			—			—			—			—



Adjusted gross profit (Non-GAAP measure)	$	5,372		$	685		$	—		$	6,056		$	5,485		$	837		$	—		$	6,322



Selling, general and administrative expenses (GAAP)	$	4,990		$	2,835		$	59		$	7,884		$	4,736		$	968		$	69		$	5,773

Impairment of goodwill and intangible assets		(32	)		(1,969	)		—			(2,001	)		—			(15	)		—			(15	)

Acquisition-related amortization		(77	)		(16	)		—			(94	)		(77	)		(17	)		—			(94	)

Transformational cost management		(269	)		(29	)		(11	)		(309	)		(109	)		(96	)		(9	)		(213	)

Acquisition-related costs		(57	)		(1	)		(3	)		(61	)		(12	)		(4	)		(8	)		(24	)

Store damages and inventory losses		(15	)		—			—			(15	)		2			—			—			2

Store optimization		(10	)		—			—			(10	)		(5	)		—			—			(5	)



Adjusted selling, general and administrative expenses (Non-GAAP measure)	$	4,531		$	820		$	46		$	5,396		$	4,535		$	836		$	52		$	5,423



Operating income (loss) (GAAP)	$	528		$	(2,151	)	$	(59	)	$	(1,683	)	$	807		$	(130	)	$	(69	)	$	608

Impairment of goodwill and intangible assets		32			1,969			—			2,001			—			15			—			15

Adjustments to equity earnings in AmerisourceBergen		(105	)		—			—			(105	)		49			—			—			49

Acquisition-related amortization		77			16			—			94			77			17			—			94

Transformational cost management		269			30			11			310			108			95			9			211

LIFO provision		29			—			—			29			6			—			—			6

Acquisition-related costs		64			1			3			68			12			4			8			24

Store damages and inventory losses		75			—			—			75			(7	)		—			—			(7	)

Store optimization		10			—			—			10			5			—			—			5



Adjusted operating income (loss) (Non-GAAP measure)	$	979		$	(135	)	$	(46	)	$	798		$	1,057		$	2		$	(52	)	$	1,006





Gross margin (GAAP)		19.3	%		22.7	%					19.6	%		20.3	%		24.6	%					20.8	%

Adjusted gross margin (Non-GAAP measure)		19.6	%		22.8	%					19.9	%		20.3	%		24.6	%					20.8	%

Selling, general and administrative expenses percent to sales (GAAP)		18.2	%		94.3	%					26.0	%		17.6	%		28.4	%					19.0	%

Adjusted selling, general and administrative expenses percent to sales (Non-GAAP measure)		16.6	%		27.2	%					17.8	%		16.8	%		24.6	%					17.9	%

Operating margin (GAAP)¹		1.0	%		(71.5	)%					(6.3	)%		2.8	%		(3.8	)%					1.8	%

Adjusted operating margin (Non-GAAP measure)¹		3.1	%		(4.5	)%					2.2	%		3.5	%		—	%					3.0	%

¹ Operating margins and adjusted operating margins have been calculated excluding equity earnings (loss) in AmerisourceBergen and adjusted equity earnings (loss) in AmerisourceBergen, respectively.

SEGMENT RECONCILIATION GAAP TO NON-GAAP


	FISCAL YEAR 2019
	Three months ended November 30, 2018 (Q1)												Three months ended February 28, 2019 (Q2)
	United States			International			Corporate and Other			Walgreens Boots Alliance, Inc.			United States			International			Corporate and Other			Walgreens Boots Alliance, Inc.

Sales	$	25,721		$	3,935		$	—		$	29,657		$	26,257		$	4,087		$	—		$	30,344

Gross profit (GAAP)	$	6,029		$	1,132		$	1		$	7,162		$	6,096		$	1,182		$	(2	)	$	7,277

Transformational cost management		—			2			—			2			—			23			—			23

LIFO provision		39			—			—			39			8			—			—			8

Acquisition-related costs		9			—			—			9			19			—			—			19

Store optimization		—			—			—			—			1			—			—			1



Adjusted gross profit (Non-GAAP measure)	$	6,078		$	1,134		$	1		$	7,213		$	6,125		$	1,206		$	(2	)	$	7,329



Selling, general and administrative expenses (GAAP)	$	4,800		$	1,050		$	41		$	5,891		$	4,812		$	986		$	36		$	5,834

Acquisition-related amortization		(76	)		(27	)		—			(103	)		(79	)		(25	)		—			(103	)

Transformational cost management		(2	)		(25	)		—			(27	)		(14	)		(17	)		—			(32	)

Acquisition-related costs		(57	)		—			—			(57	)		(63	)		—			—			(63	)

Store optimization		(19	)		—			—			(19	)		(30	)		—			—			(30	)

Certain legal and regulatory accruals and settlements		(10	)		—			—			(10	)		(14	)		—			—			(14	)



Adjusted selling, general and administrative expenses (Non-GAAP measure)	$	4,636		$	998		$	41		$	5,675		$	4,612		$	944		$	36		$	5,591



Operating income (loss) (GAAP)	$	1,268		$	82		$	(40	)	$	1,310		$	1,367		$	196		$	(37	)	$	1,526

Adjustments to equity earnings in AmerisourceBergen		44			—			—			44			9			—			—			9

Acquisition-related amortization		76			27			—			103			79			25			—			103

Transformational cost management		2			27			—			29			14			41			—			55

LIFO provision		39			—			—			39			8			—			—			8

Acquisition-related costs		66			—			—			66			82			—			—			82

Store optimization		20			—			—			20			31			—			—			31

Certain legal and regulatory accruals and settlements		10			—			—			10			14			—			—			14



Adjusted operating income (loss) (Non-GAAP measure)	$	1,525		$	136		$	(40	)	$	1,621		$	1,605		$	262		$	(37	)	$	1,829





Gross margin (GAAP)		23.4	%		28.8	%					24.1	%		23.2	%		28.9	%					24.0	%

Adjusted gross margin (Non-GAAP measure)		23.6	%		28.8	%					24.3	%		23.3	%		29.5	%					24.2	%

Selling, general and administrative expenses percent to sales (GAAP)		18.7	%		26.7	%					19.9	%		18.3	%		24.1	%					19.2	%

Adjusted selling, general and administrative expenses percent to sales (Non-GAAP measure)		18.0	%		25.4	%					19.1	%		17.6	%		23.1	%					18.4	%

Operating margin (GAAP)¹		4.8	%		2.1	%					4.3	%		4.9	%		4.8	%					4.8	%

Adjusted operating margin (Non-GAAP measure)¹		5.6	%		3.5	%					5.2	%		5.8	%		6.4	%					5.7	%

¹ Operating margins and adjusted operating margins have been calculated excluding equity earnings (loss) in AmerisourceBergen and adjusted equity earnings (loss) in AmerisourceBergen, respectively.

SEGMENT RECONCILIATION GAAP TO NON-GAAP


	FISCAL YEAR 2019
	Three months ended May 31, 2019 (Q3)												Three months ended August 31, 2019 (Q4)
	United States			International			Corporate and Other			Walgreens Boots Alliance, Inc.			United States			International			Corporate and Other			Walgreens Boots Alliance, Inc.

Sales	$	26,513		$	3,811		$	—		$	30,323		$	26,040		$	3,709		$	—		$	29,750

Gross profit (GAAP)	$	5,841		$	1,117		$	2		$	6,960		$	5,652		$	1,108		$	—		$	6,760

Transformational cost management		—			16			—			16			—			3			—			3

LIFO provision		29			—			—			29			60			—			—			60

Acquisition-related costs		21			—			—			21			13			—			—			13

Store optimization		1			—			—			1			5			—			—			5



Adjusted gross profit (Non-GAAP measure)	$	5,892		$	1,133		$	2		$	7,027		$	5,730		$	1,111		$	—		$	6,842



Selling, general and administrative expenses (GAAP)	$	4,800		$	999		$	24		$	5,824		$	4,895		$	1,057		$	57		$	6,009

Impairment of goodwill and intangible assets		—			—			—			—			—			(73	)		—			(73	)

Acquisition-related amortization		(82	)		(25	)		—			(107	)		(78	)		(24	)		—			(102	)

Transformational cost management		(43	)		(8	)		—			(51	)		(129	)		(42	)		(1	)		(172	)

Acquisition-related costs		(59	)		—			—			(59	)		(57	)		—			(5	)		(62	)

Store optimization		(48	)		—			—			(48	)		(91	)		—			—			(91	)

Certain legal and regulatory accruals and settlements		(7	)		—			—			(7	)		—			—			—			—



Adjusted selling, general and administrative expenses (Non-GAAP measure)	$	4,561		$	966		$	24		$	5,552		$	4,539		$	917		$	52		$	5,508



Operating income (loss) (GAAP)	$	1,025		$	119		$	(24	)	$	1,120		$	815		$	51		$	(57	)	$	810

Impairment of goodwill and intangible assets		—			—			—			—			—			73			—			73

Adjustments to equity earnings in AmerisourceBergen		137			—			—			137			42			—			—			42

Acquisition-related amortization		82			25			—			107			78			24			—			102

Transformational cost management		43			24			—			67			129			46			1			176

LIFO provision		29			—			—			29			60			—			—			60

Acquisition-related costs		80			—			—			80			71			—			5			75

Store optimization		49			—			—			49			97			—			—			97

Certain legal and regulatory accruals and settlements		7			—			—			7			—			—			—			—



Adjusted operating income (loss) (Non-GAAP measure)	$	1,452		$	167		$	(24	)	$	1,596		$	1,292		$	195		$	(52	)	$	1,435





Gross margin (GAAP)		22.0	%		29.3	%					23.0	%		21.7	%		29.9	%					22.7	%

Adjusted gross margin (Non-GAAP measure)		22.2	%		29.7	%					23.2	%		22.0	%		30.0	%					23.0	%

Selling, general and administrative expenses percent to sales (GAAP)		18.1	%		26.2	%					19.2	%		18.8	%		28.5	%					20.2	%

Adjusted selling, general and administrative expenses percent to sales (Non-GAAP measure)		17.2	%		25.4	%					18.3	%		17.4	%		24.7	%					18.5	%

Operating margin (GAAP)¹		3.9	%		3.1	%					3.7	%		2.9	%		1.4	%					2.5	%

Adjusted operating margin (Non-GAAP measure)¹		5.0	%		4.4	%					4.9	%		4.6	%		5.2	%					4.5	%

¹ Operating margins and adjusted operating margins have been calculated excluding equity earnings (loss) in AmerisourceBergen and adjusted equity earnings (loss) in AmerisourceBergen, respectively.

SEGMENT RECONCILIATION TO AMOUNTS PREVIOUSLY REPORTED


	FISCAL YEAR 2020

	As previously reported			Adjustments					As recast

	Retail Pharmacy USA			ABC		Corporate and Other			United States Segment
Sales	$	107,701		$	—	$	—		$	107,701

Gross profit (GAAP)	$	22,211		$	—	$	91		$	22,302

Total adjustments to Gross Profit		221			—		—			221

Adjusted gross profit (Non-GAAP measure)	$	22,432			—	$	91		$	22,523

Selling, general and administrative expenses (GAAP)	$	19,515		$	—	$	(185	)	$	19,331

Total adjustments to selling, general and administrative expenses		(1,182	)		—		51			(1,132	)
Adjusted selling, general and administrative expenses (Non-GAAP measure)	$	18,333		$	—	$	(134	)	$	18,199

Operating income (GAAP)	$	2,696		$	340	$	276		$	3,312
Total adjustments to Operating income		1,403			97		(51	)		1,449

Adjusted operating income (Non-GAAP measure)	$	4,099		$	437	$	225		$	4,761


	FISCAL YEAR 2019

	As previously reported			Adjustments					As recast

	Retail Pharmacy USA			ABC		Corporate and Other			United States Segment
Sales	$	104,532		$	—	$	—		$	104,532

Gross profit (GAAP)	$	23,511		$	—	$	106		$	23,618
Total adjustments to Gross Profit		207			—		—			207

Adjusted gross profit (Non-GAAP measure)	$	23,718			—	$	106		$	23,825

Selling, general and administrative expenses (GAAP)	$	19,424		$	—	$	(117	)	$	19,307

Total adjustments to selling, general and administrative expenses		(960	)		—		1			(959	)
Adjusted selling, general and administrative expenses (Non-GAAP measure)	$	18,464		$	—	$	(115	)	$	18,348

Operating income (GAAP)	$	4,088		$	164	$	223		$	4,475
Total adjustments to Operating income		1,167			233		(1	)		1,398

Adjusted operating income (Non-GAAP measure)	$	5,255		$	397	$	222		$	5,873

SEGMENT RECONCILIATION TO AMOUNTS PREVIOUSLY REPORTED


	FISCAL YEAR 2020

	As previously reported									Adjustments									As recast
	Retail Pharmacy International Segment			Pharmacy Wholesale Segment			Total			Discontinued Operations			ABC			Corporate and Other			International Segment
Sales	$	10,4		$	23,958		$	33,962		$	(19,349	)	$	—		$	(333	)	$	14,281

Gross profit (GAAP)	$	3,741		$	2,063		$	5,805		$	(1,940	)	$	—		$	(91	)	$	3,774
Total adjustments to Gross Profit		2			—			2			—			—			—			2

Adjusted gross profit (Non-GAAP measure)	$	3,744		$	2,063		$	5,807		$	(1,940	)		—		$	(91	)	$	3,776

Selling, general and administrative expenses (GAAP)	$	5,858		$	1,672		$	7,530		$	(1,610	)	$	—		$	(55	)	$	5,863

Total adjustments to selling, general and administrative expenses		(2,245	)		(151	)		(2,396	)		151			—			1			(2,244	)
Adjusted selling, general and administrative expenses (Non-GAAP measure)	$	3,613		$	1,521		$	5,134		$	(1,459	)	$	—		$	(54	)	$	3,619


Operating income (loss) (GAAP)	$	(2,117	)	$	732		$	(1,385	)	$	(330	)	$	(340	)	$	(36	)	$	(2,090	)
Total adjustments to Operating income		2,247			249			2,496			(151	)		(97	)		—			2,247

Adjusted operating income (loss) (Non-GAAP measure)	$	130		$	980		$	1,110		$	(481	)	$	(437	)	$	(36	)	$	157


	FISCAL YEAR 2019

	As previously reported									Adjustments									As recast
	Retail Pharmacy International Segment			Pharmacy Wholesale Segment			Total			Discontinued Operations			ABC			Corporate and Other			International Segment
Sales	$	11,462		$	23,053		$	34,515		$	(18,618	)	$	—		$	(355	)	$	15,542

Gross profit (GAAP)	$	4,522		$	2,041		$	6,563		$	(1,917	)	$	—		$	(106	)	$	4,540
Total adjustments to Gross Profit		45			—			45			—			—			—			45

Adjusted gross profit (Non-GAAP measure)	$	4,567		$	2,041		$	6,608		$	(1,917	)		—		$	(106	)	$	4,584

Selling, general and administrative expenses (GAAP)	$	4,084		$	1,734		$	5,818		$	(1,685	)	$	—		$	(42	)	$	4,091

Total adjustments to selling, general and administrative expenses		(265	)		(235	)		(500	)		229			—			4			(267	)
Adjusted selling, general and administrative expenses (Non-GAAP measure)	$	3,819		$	1,499		$	5,319		$	(1,456	)	$	—		$	(38	)	$	3,825


Operating income (loss) (GAAP)	$	438		$	471		$	909		$	(232	)	$	(164	)	$	(64	)	$	448
Total adjustments to Operating income		309			467			777			(229	)		(233	)		(4	)		311

Adjusted operating income (loss) (Non-GAAP measure)	$	747		$	939		$	1,686		$	(461	)	$	(397	)	$	(68	)	$	759

EX-101.SCH 3 wba-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 wba-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 wba-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] M 3.600 Walgreens Boots Alliance Inc . Notes Due 2025 [Member] M 3.600 Walgreens Boots Alliance Inc . Notes Due 2025 [Member] M 2.125 Walgreens Boots Alliance Inc . Notes Due 2026 [Member] M 2.125 Walgreens Boots Alliance Inc . Notes Due 2026 [Member] EX-101.PRE 6 wba-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g149076g0327104524061.jpg GRAPHIC begin 644 g149076g0327104524061.jpg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end XML 8 d149076d8k_htm.xml IDEA: XBRL DOCUMENT 0001618921 2021-03-31 2021-03-31 0001618921 us-gaap:CommonStockMember 2021-03-31 2021-03-31 0001618921 wba:M3.600WalgreensBootsAllianceInc.NotesDue2025Member 2021-03-31 2021-03-31 0001618921 wba:M2.125WalgreensBootsAllianceInc.NotesDue2026Member 2021-03-31 2021-03-31 false 0001618921 8-K 2021-03-31 WALGREENS BOOTS ALLIANCE, INC. DE 001-36759 47-1758322 108 Wilmot Road Deerfield IL 60015 (847) 315-2500 false false false false Common Stock, $0.01 par value WBA NASDAQ 3.600% Walgreens Boots Alliance, Inc. notes due 2025 WBA25 NASDAQ 2.125% Walgreens Boots Alliance, Inc. notes due 2026 WBA26 NASDAQ false XML 9 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Mar. 31, 2021
Document And Entity Information [Line Items]
Amendment Flag	false
Entity Central Index Key	0001618921
Document Type	8-K
Document Period End Date	Mar. 31, 2021
Entity Registrant Name	WALGREENS BOOTS ALLIANCE, INC.
Entity Incorporation State Country Code	DE
Entity File Number	001-36759
Entity Tax Identification Number	47-1758322
Entity Address, Address Line One	108 Wilmot Road
Entity Address, City or Town	Deerfield
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60015
City Area Code	(847)
Local Phone Number	315-2500
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Common Stock [Member]
Document And Entity Information [Line Items]
Security 12b Title	Common Stock, $0.01 par value
Trading Symbol	WBA
Security Exchange Name	NASDAQ
M 3.600 Walgreens Boots Alliance Inc . Notes Due 2025 [Member]
Document And Entity Information [Line Items]
Security 12b Title	3.600% Walgreens Boots Alliance, Inc. notes due 2025
Trading Symbol	WBA25
Security Exchange Name	NASDAQ
M 2.125 Walgreens Boots Alliance Inc . Notes Due 2026 [Member]
Document And Entity Information [Line Items]
Security 12b Title	2.125% Walgreens Boots Alliance, Inc. notes due 2026
Trading Symbol	WBA26
Security Exchange Name	NASDAQ

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 4 95 1 false 3 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d149076d8k.htm d149076dex991.htm wba-20210331.xsd wba-20210331_def.xml wba-20210331_lab.xml wba-20210331_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d149076d8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 4, "dts": { "definitionLink": { "local": [ "wba-20210331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "d149076d8k.htm" ] }, "labelLink": { "local": [ "wba-20210331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "wba-20210331_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "wba-20210331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 30, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 2, "memberStandard": 1, "nsprefix": "wba", "nsuri": "http://walgreens.com/20210331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d149076d8k.htm", "contextRef": "duration_2021-03-31_to_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d149076d8k.htm", "contextRef": "duration_2021-03-31_to_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "wba_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://walgreens.com/20210331", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "wba_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://walgreens.com/20210331", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "wba_M2.125WalgreensBootsAllianceInc.NotesDue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "M 2.125 Walgreens Boots Alliance Inc . Notes Due 2026 [Member]", "terseLabel": "M 2.125 Walgreens Boots Alliance Inc . Notes Due 2026 [Member]" } } }, "localname": "M2.125WalgreensBootsAllianceInc.NotesDue2026Member", "nsuri": "http://walgreens.com/20210331", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "wba_M3.600WalgreensBootsAllianceInc.NotesDue2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "M 3.600 Walgreens Boots Alliance Inc . Notes Due 2025 [Member]", "terseLabel": "M 3.600 Walgreens Boots Alliance Inc . Notes Due 2025 [Member]" } } }, "localname": "M3.600WalgreensBootsAllianceInc.NotesDue2025Member", "nsuri": "http://walgreens.com/20210331", "presentation": [ "http://walgreens.com//20210331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-21-101289-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-101289-xbrl.zip M4$L#!!0 ( / X?U(+16Z5'!, %V" . 9#$T.3 W-F0X:RYH=&WM M/6ESVSBRW[=J_P-*\[)E5^FB)%_RL:7(2L8;7VM[-E/O2PHB(0L)17 TI+V MUV\W0%*41)V6[=AQJF8L$E>C[VX2!R85%]YQSBJ6_%0@H)2I6P= M%,I6H6KEHNJA*@1#GZFD38>J=E'(^U)RG^$!Q.YO7H "K6^-L@U7X/,Q,(!U+ MG0ENCBKOEDQABHWO*?4SN1@+IIEX-ANB,.6T5#'JX-^ !RX[V2]\.2J9G_"N MQP)*L(<"^ROD#\>YIO "Y@6%.^#]'+'-TW$N8(.@I'LD)6Q7BCHEA!RUA3/$ MGT<.?R J&+KL..=PY;MTB"+& M;_28Y\!_P2>7WD=P#((;UH'B4&I"?D.1*)2K@(MO@4@]Y4XZU%7LJ#36^=1@ MW#G._:[A^ 8C?FMY@)1A$X:4U#WS'#;XPH:Y%$@S*JP(6AD$=-?:/ZA8T_"5 M)C C68=)T)1,P3.JBKK28@UC$:UEZJBACG.*]WP7V4V_ZTH$!31)(=89Q8%R MXE(J;2F00DOKI"?0=B='I?'I1),?F[!^5B*4YE%+73W"MB;>$MB.FS%-N^21 M._BBPYDD&@26J4*:9U_&Z379&*'.[-\'@@HG>01U((-3&K"3$6QQRU'9"%9G M1MVX)!DV&:>=>;Q3*5J5G:70N?OZ>6?ER;X!WBE-V.U2VO4K@8MX,N8H8JL"=?F] M5[=A+H;>J?(^=X)N?;^XP[W#5%V7=8+#'I7WW"O@[SJA82#B-Y+?=Z-7V)T? M=X8A0:'+="F$H7[212#\>NJQ+8) ]/2;MI >OS&\@=$"9<[Y+>R_I<[^<=O MUF[Y\*CDSQJHNGB@RMH#I;JM02=D>@*D Z0I*/Y?5K?VD^<.[7%W6+\#GE;D MDO7)C>A1[U"7]0W<;>$ZAQGDN6TU_[@YNSMKW9+&Y2EI_=G\O7'YN46:5Q<7 M9[>W9U>7LV$L+X:QL@D8OU+5Y=Y](+P\.2TVBZ12WJD=3,"5&G095ABGP"(6 MSF2%W;58H5B&:N/<<&C$HF)]F)[]DF(QFDPLE5D$LY:@V$:XZM/5S04Y4C[U M$LGO\H 5X(W-($SJ2^I#W# K7CP5=HB*,16V+A^3Z9!X/!@[*B$H)^\<\R0< MLQ$9!RUTT[J\(S>MZZN;NY?7.=>A5"'U A((PN]>X9:=@!@6+KH%J;#>>SD1?]#03GAOE"!F0K?F84 M_ VF L(>H":1NI@YV_79R:18.5QKIZ5E?)E5M00Q&<3C'!\$=0?]/FC>=>AP M"! Q+W=R0:7=-12O6GF"3:>URKLZV;PZJ=0VP6^SV<82@XNH61E M&_.U7)VV2QFY (?H2C*F\#'5FM 02$@ M&E#L9#)]0A51/K,Q>G((]P@/% $5 E(H)Q7<.X?/X/#'( 93^;3M,F(SUT7_ M2*^CE7/ZV:>.$S]'8T5SM87K4E^Q>OQC/H^D& H=/(,-JUS^$.&N7H[ K)?C M0 L!D^:/,QZ_56L?,.D;.!.E#TP&W*9NA%TSXN>XQ49UG7FVD& FM8[2.8NF"+U #IO">90=Q-4WS",$S)?B 8=%0WC* M7-H'FSC3IUZ6#6*>GZK_)#A<._8P2/[$709EF+%:?4W(*E1W]W8.9F+L+2/N MC@[.HFRP5K;V>_6JDL@<:GD/;]#0G[NG9_(W'XEM8/&+ (B!,D M^0YA@G*X#F=6UF7;QK:^C%B\+)EPR8HK]3-0!34?,4+["Q/D M[.:6M'J^*X:8QG]ADHPKU"GB:.T'_T,O\M5ZI1K$G\0MK6ZH'^LU>*-@F)' MWG&N^EC/M.$XDBD5_3F'.,Y:V>Y;Y7WRE;L]$<"4J3-I_/.+ OMH\";\O))W MHN^M#,$I8Q*"87?ML;7-O9+7X$1SO7%LTR[YF0LQLN#JE;GD2R'O6L!TW?_G M_CK1S,DN.-\[\]#R$WN*JPCB5H0MS.7X$KB,^]0E;,#L,. /F.(!:\'4]L_- M$5M 9H)TWIXB488Y6S%MO9&TV2A-^(_?]BO6WJ$"/+C,[PJ/$4_;X3PZL6Z( M!I% F$R!C,!"LU4%:J8&U%N+O[?V:WO;T^G%M6.VTE2'@)EJ3AX_X+9*C'9&(WXUE^ NT.D9C)Q$JM[.&1&GD&9NH0LX # MDH?6@[A4Q>LB[_G8IUG 7,1GN9-FE]D_]%(;]<$2@\K%L+HM!J3-7-%'JF$A MTG:Q-.H%:BT>I,-=U!M<@1()F.< U0,!A.^%;D ])D+E#HD"(52=H1XA:B#: M@"\3#41+@*F,?@C] $=YP[BL \ZXZ&,[]"(XAIFJ/I.7=M>.%38:"R0!P"@H MF(X^)J*3Y2S[I+$V V#P,-/ZF2H['PXSK=PL[?I5\@"HBL%]Z$71FWJT.]@6 MPFU3H&@ _(D[25%Z7WQ9^G;8@Z(M]6S;!%XIO2ZC3;>:P5FD]U^<>L(C MH L HI$5&S>F/^EZ]=K+C)'Q'5J5MM8Y*_J$CSM0;UX1_2Y/_J]<+%O$IY(\ M4#=\;5LK9R$XTDM&+3PK=K]^;+P1',9,&KN':YQ.>!0JIP(?U%?QOH,[<&$O MJ7+H7X:1R065/UA SL^;S[WF_@MHDW4O9]!-/I"D$=&M2-PL3[ A\; E<4)F M^!X[>",B],1J:%VR@(YZ,RA^'BVU)J;?5=C/I<+6N"-$-UE#A>V^$?EZ#A6V M!EE0A;T5%#^C"EL=TT^FPIXC07KF.9@T9J0])+;>-P,]_H!@D^DC*!.;5;@B M0#_ '@YZ3^ZEZ ==S#W[N(&%@GRS#O?,T52S.:"\DY%.'651JV0+.6SO4&\0 MB"MS?:C5QT.MN.MJR01VI5U(5F272^$N[C2&#I/94_VGP"P^\=ZYE+#I;56Y MDU8V$8R\1E([?P]OW,-GW4'3M'^VM9>G1!>P=6<.H^(FT$RNYU.[L[K T\QE M=@ \#18,%PQ"Q70MP%&T!PSO..5Z>Y>YF@EQHL=RASAXG\/0*!\>P U 4D"KX/X#:MMX*!0KX_6E#I6.,KN_G+FK%=4MFJQ6I/F[F.:"A *;VXWX MUBYU,EL2HXV)?_\;V+E,SF2]*<;$5RG?LLV ].!;NGTZ5#ESE0#> IOXH;9P MA:S_=J#_'<83\@=CJ[DE?;FKAF/^OL_-7M8%@TXN67^\NCEMW12:5^?GC>O; M5CW^\7,O65M6YH(TT3^!EZ976A>G6%D-%!@'4# ZK4/*QJ=!BIM4.YF(S#U/%#J-BAP, S_ MHEY(Y9#LFLMI\HNBI2U4Z7B*H5(^;,:6'9ZLPVVBA5_[6& 0*%%=*AD:"=#_ M8)HH=HON[5@?M[K2=5RI$5=*.M5&JH'&V5P?^!$L)_, R\F!W['^[M#FT<@6 MF2Z*)'T+$]8%,'N&;"IL?P?+%1?8,>T44> +@\Z$P<%EU"[;#$CS"Z#K<]<= M80%[ZM'O H.&V$*F\*C/AL0H)[\SZ@9=&\=MAPHX4"GT9?N@D? O);B=/[5[ M>[(CR0+*87" O$?MH=X=+CT-%C!JW"7#;>.D%4KALS%!B(<%*D]@YFWN&L\8"22, MF($#(D>RAV., V?@:+/DZB?M\W.%/B/W0I9TA*1M@QOE>8D'E(4Y"E4) '):C$ID?-IWO0[J!D0MY3#W2" M0[IXFB# =SW*]: I:B,_@5X R^5HV%5H=_,S -(WBT98-6Z@#.T@A!YPR#8H MBL1M!!F2K.-J<<(0!+W*476S2HAQ&NK=6$L$?1%U;JR[&4_5R1\>1RKJF-AP MPEF:>8OD=_"$08H00<:YU3I.H0YR-H/AB+>1=J-Y33'>'#Y#J+. T(B9C=GB MG(N>S#5JF[8/*(BA1T-'XQSFHAU2&CU GTA>%:(!)H<>'F:[C=N 85E_0*_=)"NE0I&4(4-NKS- M W)P4+0TDX/=Y@\(CQ2]3$IT1TPT@CDUT1B :0Y#:+KT@1D1H,[W4 63,K!I M7GG%'#*?,V82475%Z#I&KU-=#*-]!^I;-G3%!JBCH>)ZSAE>H*Z3Z3=&!C4Z^&EF MG^D.>."BN=&=APJ=-GU S"H7OB0,:H3!A/V-\!Z8D43W#:8$!W]L\0A?8]2, MD#2&NU>,L7\;W0*^;@;2_IT@[:^D6BS?!H&7XL'<[ETM&Q3FR04=)@C-DT^L M+;777-F/7TVTL0[2;? I;A.M,NSG1S29;+O_,O*=EDB-6* 01I$$0[ST^623 M9#)B2H. VEWT.,#U#T0>O7ZPFIB2:J,"!D9(.*/#7>;$-$0B@%<,ZI%I*D<) M)&+M+YDCS6O7LF=(EG9;TY5CIS6?7%[4!U]ETNU/.YUZFH9\,H^6QPU@S#?7+FIP MVD@2-$_ZJ&<2NP 0T;6,=@H:/!P*/I\V1JY0Z)[%!-=2L@^:!5[H.C0">HHG M4_RU_]@3"._IG)\EG7-0+%N_3#IG9'QN1ZX+:N3("5$Q)C:2PEE)(6\YVV39 M:4Q .T=0*T^]_W\S@KS$_G],0D=G *(?CB%0_+3,;OT9!P5,X4'UF7?K+[W3 M/I;"C%L6EA*V)39 D_A;;>:3>86V*^P?&]\\'#'N.AN_9R[_KW5>8>-HTT)3 M0"%Y%-+P&BEE2^['-RV.^'$D !ER/LU<\GF/5#LI[NPX;'!Q8Q6[0PQ4 &V]2 4=M0:+_ M@WJF,_'ZJ]#0*M>>E(1-"*DDN889FKPA9F(?&#FE 27Z:LHMC+@<)\H51G'D MF59V!#\02ISH^P#;:9%+##_^'"W-:DG\I==G7_16^F7]I-NSSY>-NS]N6F3Q MO5)/$F5/KD-)_+ZJ'*7,EHIZ,S:"."$$?38-=18>HSB358ZB4F7R[<)E ?IKU"R CF1< $0 &0Q-#DP-S9D97@Y.3$N:'1M[+WKH4[ M-(G-VT([!-=_-NC^UMX^EOK7\RE+'6%A(M"1_FZK\J2=@"@P$= M4$EZ5LSN;>.B#OED965F966V?_;_.C]N_^QVSH[W]]K]7O^\>]S]_PY;K9+4 M_N+^RC[_XC4@[9/+LW^3DQ^GE^>7U]\*OW[V^MT"_P/9WV/M3JEN4_.X?=;[ MF]ST_WW>_59X4H?VPU&S5%/U E$T=:1_*VCTWG:^U;Z:-1LKYDC5#VUC MV%^)]_N=8=O&V/WHWM#M0TO]AQY);[_?*V-5>SGJ7/ @Y%#JEZ*-3$IUBYP8AFV1CJ:IBCZ@1=+3!Z57VGVP MZLBFF! M_4#)O_Z0JHVO[=OC4V,\4?27]I?;8_Y9\^MGXE"$#HFJLY4KY.:!K^AJ:@X> M%(N2#N][S-HL=#3?;'_OM9V_ZR?5?B"=,2.L9;"6](2:(ZJ34\.<&*9BJX:^ MT&O?5'1+&?"_^/HI\7&LJ<(FP:;(O\!F/+:(H@^)-;W[+QV\_F%@,+3XURUB M40= -@-5=_ZV:F7%-5-\4C6-3&9?XSV-E?\:IFJ_,'[8W^,?>&3E\ZU_M9;R MR-V,1Q2+/%'6(_O_"F&#.&,PQEK2CTEM165CLXF/E<$+AXB:NC,K17OMD5I\ MA=VI:4SH CW/5&MB6*SM#].83N9(NF2.LV%5_9%:M@,ZZ_CT0=45A]8]6]%> MG)]4V]K?8\.Y%'+&_\$@85,G?*VZ89.)8MJS9?E@+9'^MNN<'X=__8*R7DV- MS<0JD@O#?%+<:9TS?F-LHBK.+#Z<@>\#HEJ+;&2Q\:Q[[\^LB\'48GN5[;W] MO8%F6%P>O'%:D4UKH$T=*6'2 54GSK#*9**I ^6.B0V3CJ::8AOF"__4-!X5 MS9HCA,MCBD_L+$S:Y997'AHZN*IORS$IZY]M8H6Q@\UFQ+"]4S76@+K;Q*.A M,T-KJC$QX1%FGD/<>>C&$[GC?7+N=#K=WV,CLA6S'J9TZ$>$=\Z);=)[C1'0 M:,>_2!RD:8C?RV,1F(E#7CZU7X'O,D\(2UY%)IR+B4+]O]XA(H MBX3>W[-1U4?Z2K3WX_&_6)3C17XS^^9I,: MYHBQTS]L50^,)B8=*ZK.B>C;>GSQC/&5D3==OO8B8;*$C3ER]I!+1_XURS:G M WO*OL'Z9R1F@L:DCZK%^F>,YY&0S8,QI$Z??,TYE?W0.#K-3&;;3X8WAL-L MWK#6$;G550[(C-1HOVEMZ@:1:.#+9$I\S.8 M8>'N5/8! WM_[^WH?-U93P^JP[MOS?S@+DA, MLCO]6-1\5 ?\K_SC,?\*_X'K'R9C.VM".8^R(^15Z,U_@TE80G]/^2$S9M+. M&"Y(Y7='5LG14*S7?3!;L2,)3;8@=<+V&!-@0_;%1T:9>],8>\+.U6SXMAN8 M3'IQ>>.LS]W=C/.&E$L6QF%.EV]48+)LR%AT3@0NH4:1\:PRM5^*?(M;CE!W MSD2'(HRNTS'G7'CSNV(1!AU?@8SV#A95,N5T^WO MEQ=]9NS,K)L'QMF'UD09T",F#TQE4CB><=&A1H?M+[S]L1\(E_PSU'S2RYC: M%D>7\\%MZ:;DM/8ZHU-;Y2+RZ<%@X#"1P\#E?V:0V*9Z-W7XY'7CO*D )6_" M'TSW:HOI[N_-*3K.QO14W3MV% P9*[L;<7;BW/Z/*\NOZ61ZQXY@3L(>/R Y M,[/_ZS^P7MD/;JL3JBN/*M_K3F^\D[_HLSHPG+:\1>>!\>=0>?L[TX@TNK#? M++IX*/@V'=EVS[FTV-_;=!,97!_RMA+[8;8M2Q_9=2'V38_I(T-7^RFR45U5 MF1[.E!#CD9IL!7QOE M;Y?W9[F'$ MCDZ#D\+1/9_>-!>O&UY,LDMU+=5JSI;YMBU2I1[VX-V;C MJ(Q>@U=5R5-!9UKL1SJ<:SR9;!830_=46::9\&^RV7%U9@E.L0GF4\I&8N I M8ZX0O^[L=U1\U139."^.V<'XD@RGU&$L]EV^DA(W[?G!RW0TBVE>3%ET5"\F MVP93EV.GCDH_U9VOSWM_LJ/"<4/M[Q/FO/6$RZ46C\P2A MXW?TX!]-V+P.[TRJ_-_AG\_C+*5PJQ+QP]V]$?+ M^5^!_.J=]7]^*TCE\J=7-\=I]Z+?O1;'2;;,$]0Y_W'=[5[ MZUR<=HND=W'*-.F+,W)S>W+3.^NQ+KHW$;B&-I_;Z>7%S>5Y[ZS3[YX1]LL9 MFR;[Z:;//OB+D?:&7'XGW<[U1>_BQPTYN.Z>=F[ZSI1O+SJW9SWVM<\[G? ! MVR"LA>::H_1Y0)D-RIB66([/PV/GSVM\D_*6ODG.Z/W.R7F7G';/SV^N.J>, M'M\*Y8+S^U7G[&SV^QR/GEQ>GW6OG<^].;B?'#+&/N]YOGK*';+,275OV,SM 9 M.D-GZ"R_G;%_KMT/KI<W]^-G_5I#G.O=]S'04?OQ>;-2D62VL M'-^GBJJ.87&D/!KJD*PYB)N^R2Y0YE5=>)M4#"UF\_=TB\.3RW[_\B]&Q&=B M&1I;P!]EYW^;=/5&*'E1NW@CTY ;%C.UJ,*4K:]K1V9JVO?>S6GGG/R;J8ZN M)A;M@A)BJ&HD32KU:+L!=W_,W9$S-[]$B8.K-Z::?VEI0:%2C0&&,F 0 :I ME2D9OV"KGW>_]]]/]>ML+=>\B\U "7RD;#2C2$?,7I-5-!PR%J6 -:U-8H U MP_K4&EDFIKKUO]LJ6RM CF*9R6L!^8 PU1 )BH$,#!+'H (,$L>@FB<,UBE$ M8F+4O^QWSG'JX]1/$42"8H!3/WD,<.HGCP%.?>'/BUV>^CP8T9VEJ8X>["/9 M'_ U[V/>)3UD50J.]'?-GVVV52'[+ X.IQ].#>QI1'RSN,3 M'H0;[(3D:]OF0-E\#UQ<_KKN7*WJ;SD=_PS9P>S$=0ZMV:37E8KD14B:M+MRKY9"W/\ ]E;B7J[G'/#/TS#XF45C'O53OI>,*K F4AZ63A*Z\5Z)61$$T)? M$T"MT4#(ZPX)WBB6)1!\AP2O%5NUD)8?"+Z=2*G(V0OFWG%H:QS R/5BN8&' MIFD[HAM%J8X'ICLEN R=:+O<<00A.\D4&"9^&(;A:EL-HJ7IW +RE M$[B;,]D$KTXBS9%$-5ZTO/A:4]ZI #XREW),;()7<&+LEN 9O*X4F.#U8CF#2F@6CNA*L18V_QV;V6)98>!NYQN4?"\]?<82XC0U+^,*]BH^<.](C, M]Q1CCC?NBSQ1J89TX",O4OYX)O>Y,O*'>1/Z0NXP/Y#BSJ68%C]!_K"/Z)U! MBO<[=,5WSJ&PA?V0# DW26EH@@O"3#;!ZY0HKP,O)Y2_0=%'1-4'QIAZ]X%) M7_V)'$-S4(NH"L5*UDR+0IT^[%HR(EUW2&ZI**%^]TYEDU2LAW7RB"M_!"9\ M/6Q!*P'Y/ /QKBC5G;XS6BI6I.QE+A&:X#49I_1NU2(9'+Y#@CQ=S&I$,\0Q414]5 MC*9X6(I9(G^8APVX >;IPUP*FQ 5H*&R8EJFY3DUJV4Q?%5IZ3OOT3.6#FH-J(.9XU+3[8]&'7 M"INX1T 56&!R2\70#YU!\"V?GC2DD/<$XLH?@0E?KZ$:BH"P2,5RV *L>'R2 MQ..3:O9BQ84F>*T*Q6BW'%Z&8K33QR=X&BH@++7P-6KP^ 1N2@&:P/N'VR@]'#R<5!WO1QKF@]Q M [[3CUVCE;VX,X')+17+&:P!(3#!#Z1B,ZS=)Z[\$9CPM7)HJ@M'[@P$M%:K ML<;/I FTU)S14E%JH2+9;E\_-$'PW7)X!03?Z7/0[-7RR<+I7*Q$%*N(YR;P M2V;,+PE8DV^"YR9Q/S=QJIS8RC.9F,:C:JF&3@[NJ$[O53OQFBS*=[DG FGR3# 8Y M7QF6[;AYZ4+(\;UIC(GAE+RFOZ>J_4+&U'XPAD35'ZEECZEN6TGZ@'/\5BAL MXFH\*<\=RQQ$E(8 ]7#3A[V4^^>F^<,\SQJOS=-4:' M9:3<)S'+'^8H@)P[R ^B<;3#'DP?]/_Z0ZI)NU^7D.A#98RG,CK2$.$J1^@F MN*'+9!.\"XGW7<@%M9??% Y86U6?LL^),:&F8JN&;N&=B*^7106\THSU&B\] M&GCZL&O4$8FZ0W(W&XA$W7&JHK#7Q>)*'X$)7T'M31%AD2JQVL1I BTU)[14 M+,MX7;C;S#EA,WJ!X-L0O-7,W@L&@X#Q?Y,;\E#+]43]@F7=)^&->D_ L MD3_,PR88!N8IQ#SN^J*"^OZ!?$1ICU*\VQ'Q]^[A4#/64@S0%#/(,PUH#;G# M'$\&A$ E">AKT82J8;NG"?/U0EHQIR%/BTF5/NR:R->\TW#'&LB]VS<@C; )I<25/@(3OH*" MF"+"4I6CR9&#-R [?9)0QL/!W1(\[%,I$'S+5TZ5D)LV,:?F0A M%]6EB'BAW(<+Y0_R SF:M_?8[BG$7HK[*4E:L$>8X#O>"'LW'EIS3!WO0(&< M'2EQAYJGA37RB#W4"1%@222R' _*0 M1^/.!>2 ') #['-KAN^>0 MXMW5X9(.MSDIN,T!K,DWR>"CO/;)TNI,BY=SOQ1M9%*J6^3$,&R+=#1-5?0! M+9*>/BBUOYP$/(RS=1G'B/GG(BUB/U+9H >5 E^",@0<,0GS M4K-:BW]8/E J>"2G3-#BE9G!!/EF I[1+\)S)3/G1D[9H=*H0":DQ;63%)-4 M:]$='*$4T70Q$310'P])14F&J,G]>#>J,!)H#V MN<9$*;::Q(Y!)@- MQIML@?>V3+5V!N__C7Q.P>@@I.#:AGF"4BN5/0$>H7L"/$+W!'B$[@GP"-T3 MX!&Z)\ C=$^ 1^B> (_0/0$>07I:XY2*+P(>3= DW4W:PB5:BB2J^RB^L.YD MI#Y&Q:@8%:-B5(R*43$J1EW\&XQ -$&3T$9@$B8?:5^]>K7&BCE2]4/VI:,R M_^OL ^\;[+/7CS1Z;Q]52N4R'7\E-GVVV52'5+>/#B7OP[F)+9FZ8VV>+J_! MR>W'J]W9D(&J:T<2J[;T46Y+BJ!CT5]'B0Y#H]Z*" 60/P#YF_4(XG9!_L!" M2"HV6E6(H<2!J%2P#Q(DO]0L@_P)DK]8KD4EA0! ( "D>@2/Z0! 4 !:C:B, M 9 _ /GK,K@_2>VGV)0B!P#.2C1!DXQ$K"3HOCQ;55TL+L^E8$^Z=S'(8AU7 M5(3*'>:-:'(_ _,T81Y--1A@GB+,F]CGN<.\ LQSA[G,,_( ]'R!7L>!GCO, M#^+&_/-Z8 %](M#7:MCNN<,J1P%[3YON#M5GJ#EY09OIZ 3\,X-WK/:39#L>4/>*=.$G9X;O)V* M2\ [-WA[U9& >)X0QQ[/&>).S2,@GAO$ZPBFR!7>7J6BQ*]< M<:VH$_6%[A M#W;9X?V_8KJ(5W25S9[2)TE20%3 (S11 8_01 4\0A,5\ A-5, C-%$!C]!$ M!3Q"$Q7P"$U4P",T48/TM,8;A0!@-$&3/*1LD4)GG#Y1+'7PKL+1A)ID8(S' MADZL!\6D1SO/0;V#@P6C8E2,BE$Q*D;%J!@5HR[^#78FFJ )'IJBCE$$)43* M)?Y8,'3/J" 2#H=RJ8D#4D;AGKSN M8I"%$Z%J0\'E$O5P%ZOE#O8+R M!SE$O8ST2[E#_8#!'O=F1XI<4=%GX".I(E 'ZKE 7=J)MP;7.&B")@@[%ZJ^ M443WZ2'SHRY1OL,6C197NQ:3Y.52*V12:0&5&S%)+85V*(#4FPH2*0*VAB#9 M3I!40U:@ '=O3.I:R#3A(/7&,CNLD0A2;TSJL.4M0.K-N1JR>E>RN@&NW@VI MJZ5*-,&9JDUM.D1*0HR*43$J1L6H&!6C8E2,"DL33= $ ML2%(28B4A DX7Y&2,+/T1TK"1.404A(*@0-2$B9-?Z0D3)+^2$F8-/WEJ(X! MT#\0_9&2,%GY7\?YFR#]JTZ05[3TA[\23= $D3%(29C&Y\Y(6)5#U)&2,)>H M(R5A#E&'A,\CZDA)F$?4D9(PCZ@C)6'^4$=*PCRCC^1T20,"U('ZSBPXI"1$ M$S01M\F2K9.72QND) PZ)U&U:S%)CI2$2$F8/5(C)6$"@@0I"9&2,&ND1DK" M7:8D#'FW!E(C):%HI$9*PEVF) QYMF:]5@KM/,[VS6HL9&])I=#7(R#[UF1O5DNA_?<@^]9D M;]3 [4G(]CJX/0EN;X';=T_V5K59"AU' [)O37:Y"6Y/@.SE5BEDG@J0/8C> MWBJ%#FD'V;<7,E*DF@R\A&B")AD)"4DT%Y]3HA*>0QR%N]- 9&@@27@.:_"E MP'.8%[+7&Z70P=<@^_9"IHPC-0'KLH;+N"3(7BF70K^@!MFW)KLDP4^>A,,6 MW)Z(Y[ 2O>>0]?2EWSDY[SJ=?CGK_"SR\.D1XKVI+Q8!3[4SVMRT_L/FURE,.O2<;L<_=%R_E<@ MOWIG_9_?"E*Y_.EU_:?=BW[WFG= V&Q8-][\VFRVL]4^J4/[X:A9JJEZ@2B: M.M*_%;A;Q/G6FU=EWJFRU*?B\YY*RWTELWD-G&D4G(<\G?,?U]WNQ0TYN;SL MW[ 6Y[W.Q6FW2'H7IR72N3@C-[T-F-5K98F*?V\WMU=5Y]R]& MQ,XYF\[WR^N_.OW>Y04YN.Z>=F[ZSNQN+SJW9[U^]^SS3N=VW?W1N3[K7?P@ M[>^7%_U7-!]4FQY:$V5 CW3CR50FA>.+RXO#'YW.5?L+;WE,OO4[:X)-=V'6T09&U/=MC@IKXZ754&I@?*/M8TXXGM;Z+J;)>-GD!C'NBV%/X&;**9R MI]$EXY&!H@VFFN*\F=.';R/L[[$AE,' ,(?L*Y0\J?8#&5&=FHK&.F5_81#Q M+[$F4UYR9,2^J[+.&3DL=WJ4W.HJ;W-CL_XMOTM4IP,ZMO@VX)_2^WLF-QP4N;;!#GXRF)HF MU0<)]P4 [J86 M$\N,T^Y-8\S;J\:0;SWO)SZ>S>@T?!5 "]]GK&H;)J.7YAO60\N1B@OLQ7@X M H)9#\94&SHR[XXOVKES,QG]V%!\XER4N&"R3^XL6[69L'#V-/N/?\SHIK%# M6E<[9.MFO_UWJ@\<(<%E5]&A!)_CQVCZ93;GX?F]##UZ$ZW* MJ2EX>WS1[9-NY_J":8$W3,Y?WMQ\=E32L][Y+5-(R;*_7W49!7YVKKN,XK?' MR_0^W_!\XC81.>V>\SOC4S;TMT*YX/Q^U3D[F_T^1V4W MZ:[SN3<'+PTO@^:\G^9LWX]_#M099H 98 :8049GT-XVV&Y%-%+5%XU4C_[18G-)\-'&7M77 M *0 J?$7NWI;I+QXHJUP4\J;I:\_.?[>NSGMG)-_,\U@36J<0 O:&NG::-*/M1A"VVX:;MF(FAUODLBR%+Q^^DQ:^9=:#K+.?7!7Z_Y )L)V6636;'A(Y_OYO-9&"Q4 M;^^FCKEE;VZO[#AD^Y=B_^25#S W4?>/()KBHCZ_?!^&4RBYCO&_ZS3&Q8EL M(8/BT*=$(8N "N;2=<@9649*OG]6D1>UJ)3OB1 MPH5; Z5H>HH6!2&6)&)/(#/(G)V>8A+=*_Q(0BP9)RQ.6!%0$&))(O8$,H/, MV>D)9([_!-W(Q;#:O;"3& YA;IDC'7%MD]3ULN75*&!-1R\QP-H6)P?@6W0; M?_E(7U\^:L[+1\6V3?5NZCYDM WR2]%&)J6Z14X,P[9(1]-4_ABL2'KZH$0. M^M(X_5UI/>H=4NG\.;,NE5*@K<%_[DXH0#]+&1+8+T>5%KO;I*V[W@= M,[&!/L\($?9V(?N8-.KOXC8#SB]6:HM.QF:] 3)&("&D8J/U[E8PX!1W(05$ M)VBED@J^#'$%*Q2YI>:[:/]8#CB<;!M@42S7HA(EN98A4E&JUT'(\(1L-2)0 M?T'&NIP*;LS*F58I-J4("!X@GLF/$+R-<$O!VYA20(2%=8E4V;5OL>-+368; MOLQ.JCXPQM1S-Q[%YB'<1C$(?>DD2%1&C'38J5J&.6/.875-[/^48(PY8\YI MW_^(*8$Y(+ Y %B3[R47,24+1A_]/57MEWD5&W6/GTEC]2T>7;@0R=-[)%3_U%J?V%?$.>V)Y)>%GR44K':#%Y1;+,K M-_'T55&HSV\\0WJN=ZC)B4*U1O!:;#FFVH%4#EYPQYO7YY@M4(')5VT)RW0[ MOBR+@[JMX"6X< :%9.S@)19S+$W%E08"$TVJA-SF^21;-7A92!P]:ZDK5T*J MDT&",^"O@V,'_KH4 R(LK$NDRFZ].GT@Q)7IP]P;TA9=QC@&R[ M(QM\;X'(!N=;G*Y-_CH*SC=X:43N!R^6@9-'JB#F#FA1Z:P!K\KUD,-#MQC9,2HR)K8Z#Y7G+P\/2?_TAU:20?::V1)@H(,![ M%$A; M4".'A!M0!4@]D3)W$1;YV8+QG2()"/&%3;GFH"%ZL1F&IAB]#@Z/E0 M&VHA[ VN&<%[@<=-,$"$A;4M7-A;;SQ15),G=2/&/1D9QO!)U32BZ$.BZK:B MC]0[C1+%LNC6D7!U>.?@G4L+"+&3&?3++/WD8KD,BS.(=@^W7;QL&6^B;'CN M(%1!/] OD_03N%Y\!LZFL-2%6P_^GQ3Z?P!K\KUD-I!NJ(S9H)[K[I'J[,,7 MHAF61;?UW#7@N8/G+BT@Y%E)!?TR^UQ&8*H=A YY^)R49$R/A13V[35<=Y"J MH!_H!_J)2;\,'%'QFU!+'7D?&]YPYPGD:Q&I%[CS! -$6%C;@D7I>5,_N>SW M+_]:-O=3:MJ*JA.-CA0W=L^DHZFF.!Y 93 PIXIF.9];U+8UIX;KMC[!9D0^ MP5$SD$ M0"HVXCUZ$*CV40"&TZ?_WZK Q4?21<@J0H,#$%(N5IM(A1"8 RLM<2LN92!@ MK5)L5*-Q9>"TBD+(5B3(BF@(&;8P"0CI'?L-E+B*A)!U65S]*0,G&;.[XJV# M!X\>7#]"NGX :_*]9"3F.AYU>YL3?8,)I#;'0$1TV*D^A3ECSF%51.S_E&", M.6/.:=__>" +K5Y@K1ZP)M]+!L,OVB?'G878"_N!FJ]Q%_1Y0G6+?CYJ?SD1 M6KF!D@?E W.&DH?]#[[$G+'_8>3!&DB=-0!8D^\E(S=R'YM]%]1V,IN[=A]Y MH,,1C[8_&"FJ_MG)=+YE3J-6#O*>9(&I)VY9;8&) M=B"#XX(3+_33&:0UCU\HKCN0$L,@/>=2Z%CQ' L)A(<'()JXCYI M'P>0U*L MU340/ ^?CI ^'<":?"\9C,?XP9./&SJQ%(T2XY[0WU/5?B%C:C\80Y_+;DOW M',_VEWG_'.H0"@#" 3QUR7)P[#P*^H%^2=(O S936"$)SUTN.!WT _U O_32 M+P,G%0H3PB&4GE[@YQ,,$&%A;0L7DM<;3Q35=,+Q(O3[2?#[P>^7%A"@T()^ M0>G70/[+K')=!LRHL-R)V/%LLSCH!_J!?NFE7P:.*'CZX!)*3R_P] D&B+"P M+I$J._3KK:UPV*?F6-456S5T[O@"!2!(E $BC$;_#@WH3R!";*UU8$B4$PCB@=2(V2ZBK6K MVO6[@_R!F,6M"-TIMJT:5'-:>E7CW]VXJX%3'W\E%<$3[ MY+@S'QGAQ438RC.9F,:C:JF&?M3^%#T$;6VS41400[RC?I,K?XI"@@' MH:/L'1@TD%CCW! !$6 MUB529;>9:95GHHXGRL#F=0-]&6KAS%L6]!!S 79$/:R_W2N'G5:.HQX.6J!> M".I)8+Y06Q>I;7= Y6HEUJ(?.*0VB?,1GM-%IEX=*8+#[/_0"5OS3+V6\$&U M63BCY%ICYZX\!.G!Z2.(TP>P)M]+#H+TUM8D[/Z>JO8+&5/[P1B2]O?+B_ZL MOZ<'U::'UD09T"/=>#*52>%8-_3#@6(]M+_PEL<\_B\I+V&>JSI6JK&^O=J MM&)8@'GF@9!:JG (YP_":&X25B\)T,4&72WN MC +C;LHGD<)@!T*'?]KCA6 MR,N9T&H1]*&DH _I;A<'V?Q!)T53_PK8)6&&2-&(7-@AR6$8S=,/ ;8?%*)W MHC7F3 AKIK/T%@;7+_#3)^VG!ZS)]Y+%4&K#5C1_"/6J4A:A+3VA[_:KY5CO M]D6Y?1 :@R9B@,)0+_1K\SQ33Y)#[O].G(T:8-+9.H>R-58G<0XG#8) M[Q4^Q%)DZH5/A9)GZM6@&&5:K2D1.Q)2$().2D1>Q*2 M4''$V*0($RA%4(JR#JY0DQ*Q)R$))>2D1.Q)2$().2D1>Q*24%"*(H\.7O07 MLG\Z)^==9R9?SGI_LP].J6Y3\WA_CSC_M2?$LE\T^JTP5LR1JA_:QN1(HN.O MQ/O=NQ@I\X]\X8!W]-XPZ9&B/2DO5H%UU_YY36YZ_V$+JQ1F73HI'([^:#G_ M*Y!?O;/^SV\%J5S^]'II<]J]Z'>O>0>$S89UX\VOS68[H]23.K0?CIJEFJH7 MB),-X5M!H_6)_6X)_".?S_3M=[_3M'#LN:7^Y9;1F'7VY M.G:(O'R&[R9(_#-L^B&]KSMG9[/GLW=W-;YZ'"_LD''V!NHNX?033%X*^+-ET_1HB#$DD3L"60&F;/3 M4TRB&Y&".&&SUQ-D$LB(JA/#?J#F[ ]>:515?Z3>M[:M>%J=53S= MRE>4C1%\58R5L+6G\BDET.G98R-N )3+6SAJ7Q2+>0NSR?1Q-V?(2Y, M12%N+9KB?SAXMB?]O_Z0:E(,,\N+7 #]0BH^.(V"*#ZAZW/@.%I-W7@+3*"F M'IP]0CI[ &ORO<3LPXO'8Q>/AKS-21WZ_D60 (48Z;!3/0ESQIS#:H/8_RG! M&'/&G-.^_Q%> 1U>8!T>L";?2T[#*W1JO\56'&B&97TFBFV;ZMW45NXTZK0Q M] $;V#0TC34C*G]C1RW;.HHM9 +*84H4 ,P92V\K^DCEUI]B673K MB/KZ+* ^!HU(E""2* +#4JN69@F$/$?G@7[AZ'<@A8QL+AQ_SB_U4L%]&8AW M#,VEZ\ZIN'D8!U7>!2WH!_J!?MD_JN*WJK9Q]NWJSO;85V#RK7755U]R=;W) MM\E?'6]HS'2HY-I5_:;$1L M%BP4"TUDH<((P&@UP,C###8JNAI[F,&6E5>L2U35+72_QA!H U&[ N MD2I1>R\Z@]]3U5*YC^#0I)K"IZJ,#6;__^,X#K;T$L@[CQX(K"!O<:\"_5@L M)0,+Q4)CV.XY\@Y ^&&K8*%8*)P#.W8.[/HIZ=HB"8)>7Y[WOE^2B6D\,N/$ MLT+V]S:W0ZH1WE8&JDRT$3_MKL/%\W^+S(ZARTN)H2!D$,6 4BR5U62 !) M$FE"XD"*<*Z"6.89/$0"P 150#@4(?: !) $D "VD "2 E3.7/%3;V\V[ : M>7WL0( 913KBVB:IZR7^L!K F@U8ETB5J,-J^H:M:$2)+ETC.23\;TO3AJ)X,O+X5:_%&UD4JI; MY,0P;(MT-$U5] $MDIX^*,T%71%C0DTG)Y)%VM\O+_JSV3P]J#8]M";*@![I MQI.I3 K'!Q>&?OBCT[EJ?^%-C\F8*M;4I)\CJ;J;1. Q(^F?BY./-/28#="J M-@(-$=P2;?/1/D1$6%,T!7A*14F6HAUDYXAE#A*Y6@TF !)?"9/,^V0 MY$Q[J!6E>FNGVL-2_[P?Y34.^G6AAO+.0PU%O#T1HB?<.H+,V>D)9 :9L],3 MR PR9ZVDF4((\-X,!_"S+YQS@<#Q@?QBKM"\*1HB&5_P/AY?YO[?._7MWOZ9B7*2WI1(OAV1+S&AB&M ML5-E1\O=,* C(\O=-& Y(\NMB++<#2.G=D06N1'I\ZF<2@15:X M;+E9L&@/;'19C(H5*2Q*$$TO6]YM =9T]!(#K$ND2N1E+4U%M^X-<^Q8ZHI& M!H9ED[&BLW%XFU6U2KC*] MJZMMH-OE0<6M0)IM;A9E>D>TLBW.,NZ#K"1ZU HCSZ1:9+C^GJKV"QE3^\$8KJ^'I!OZX4"Q'F;ED&SE>4M7 M@92>R\)HCY#DCEY!R0:="PO%0O.D14,$9FW#'&QR[_@Y]:MLY&&5HC"M,,+O M0(KLIFBI_\#/,>T$KB4WSHLIZ/5E7WDFZIC9)S8Q[HGB%(KET8ON[>7^7A"C M) +#)(GZ*E%W&$#,;[H1UJXE;D&:6Q0#*G.I3$LL-A*;*!0;SW77^R5#,&P? M#@X88H!!2C,. E59BQLG&6I %F!,\V[+$ S2]N'[P"%Z'+:7:1^4N03YM]\& M&SS'%W8;Y.GPC] 9MF;LK;QE265I%R;G=:0CKFV2NE[B#[$ MN3>6HO.3Y4"B97S+M[*]O$JVEU=-]+@51Z)MDE\"V?3PV&)7O> -C6" " MK M>Y/ .K^<>8X[FF[MD1#CS61LD3ZQ]13\ CF]]\?I0TD8%(18DH@]@G)YRPR9^PR#H$UYK KC7 FGPOJ0R# MVCR>^N2XX\1*L:7,14E%%1ZU/N/1P86A'_[H=*YF*8_&5+&F)OV\ILZNN,]+ MMJBX&RQ4F%?F+6]8H#DR6U2,&N?9Q7/#"M3;S'JG>&4,$!Y6 CS$P2.HP ,@ ML0%23CD@ KTMV@5@U7(%*D.&\&S64[[_LH8'- :A\&A!HQ8+C[3OCYSI"Y5Z M, 4O4F>\'^,UWOAU<85RA%GZ%O+RD26)^;X2FS[;AZH^I+I]5"Z5RW2\,)VE M2?=<7GG_[Y:I\T2\IA&B)UQO@LS9Z0ED!IFSTQ/(##)GIR>0&63.3D\@,\B< MQI[6> T"QO")%**$7M#+]KVT$RB($9^O-O#?PHV*.6/.F#/FC#ECSBF9$'M[E]>!7]&L.WSEZ6#B?>*XN/YQCD?#!@?Q"LN^L&3HB&6_0'CY\DE!T/: MGR7E\_'1K,]XPX.D8KDF(Z X>[#*D+B4JDT@8N N,C-:LIQR:-: M46-RKH6G3($BK1!(AG@]$7H"F4'F[/0$,H/,V>D)9 :9L],3R PR9ZQ'XZL.DG?GY7MD^,S59N^>T=RH!F6]9E,J$D&QGAL MZ,1Z4$Q*#HE7Q(:U\E>Q.>!O1#ZW;VZOWA_^S=JGK^21FK8Z4+1#15-'^I%C MM4NU]A?VC0 !'LN#$[;)^NK]^A8$<5 N53>,K>3-/R\/S8A;98MAX>72IL&' ML0?C[&K!K0VCQS*RX .YM&EQD*RQ=F7#N*:,(%TNR1OFI,[(@J62M&$6^\PL M6-YB*V=BP>4-GZID9,'E4CU?0JM:DB(NO+-%<.FNKJ@":^B^I/IOHU1Y;OSY M%/M+,NR_X7?E[^;C[TFO:?=GZUF:A=]]?CZFNFWQ=^:>*:"/]O=4G5D,U+,@ MUB3EWYS!-HZNGFTQ^N:I#3! M,'K)?B^;[<>TW!8M&GWV S7)S-ZCSQ.J6SPS6)*G "\3G^%3X&##%7Y>OPRQ M%YIY)-D"FYE>X+_^D&I2L/[3M="RXZ$&DIE ,MM"AQT?TB92!\>'Z OD2&X@ M=4+8@WX>:./&).H;$T]MMI7G_;V):3RJEFKH25^7'&QXG9!Z^<"WSR;7"EAH MFA9:S<-",Z]N,B3EO BAC:#,Q$)SL3?Y0C>Y"LS"0G-SK&PBC&+0LW']@E[0 M2[A>,GW]0G]/5?OE[/, U-X^DC5-VF)C--K0^D;X)E4Z+N,%@DW\;3 MC=O3FETD-M45LY!T%D@ B4VETP9J-Z03D,@5$ANX:H$$S@D@ 22 !) $FE$ M(M*JEB*&%@1P]T045,^F'&U4??O$\T31(1DNRV2Z<0K3]O?+B_YL;D\/JDT/ MK8DRH$>Z\60J$Z;_71CZ(<]SVO["FQZ3,56LJ4G=M*?[>UL$5M2)/_/IAQ$6 M">[.+9)Z!=N?;GJW8*5GPY0,%KIL3V:!EG=?XQY )P%T=<.4G ZU4"72PT MG0^@6P Z#T!72_*&F=$!=*J!EDJ5#9,J ^B4 UVK NA< (T=G1>@90"= Z!K MI?J&M3SB=%^ORIN_80QQRJ(ZT0MZV;Z7-DJ>AQ\5<\:<,6?,&7/&G%,RYP#Z M\'8!&BAYCKEA;I@;YH:Y)3ZW_)8\'ZJ6%S+(OI.IHN=N%K]-OIN16J-NU85\ M+3A?U63SR-(;7O%F9L&5?-7\+N>M!+:7&V'3%;\^I$S]PMT$9#E".H<+EH*% MV&6PV'F&GB'U#5O1B+)]3IQ?BC8R*676Q(EAL*]U-$U5] $MDIX^*!'^@HT1 M8H4%(N[3H9@?]D7\$C\VF0($@$","$29%P0( ($T(K!]<08@$"D"FU1= @*0 M0EE&8)-:.$ @UCT *90T C4@D"P"\O;Y9*-]*[#H;]HH*.K=[7,4B<:KZX.] MJ^N#O=$+>DFZE\TVK)C!%P$)R8$Z"1$@1 M ^@L 0W1#: !=(: KB+C8CZ 1@Y5 V@LP3TID'L #KM0,.\R@?0E6"B&]F< MT MZV6$O[4T"YOT[Y3F:2Y2$9&?L EVDGI*+'4@!<4#FE/4$,H/,V>D)9 :9 ML],3R PR9Z(?(A(#7M$*$3*I68%B(B$B.0\. Q)\=R9_]T3LZ[3K=?SGI_LP].J6Y3 M\WA_CSC_M2?$LE\T.E?F0J+C=_4Q^$>^$) [>F^8]$C1GI07J\#K9?R\)C>] M_[!95@JS+IVW44=_M)S_%"5"Y_>O5DG'8O^MUKW@%ALV'=>/-K ML]F^AG"H0_OAJ%FJJ7J!.#G5OA5X0CC^+?:]32MUE.WS1 M[9-NY_JB=_'CAAR<7][76A\WKFZZ1[-?ECCEN$=>UOE6Z%<(*?= M\_.KSMD96\OK[S=7G=/9[W[@9MX@!V+RC:R*"WKU^WA?KC+,YUQ WL\ND-O6 M2'1SZ;W?./Y.YX;S%X99* 5#UC!*J_?*NO(NJD\Z8 MFJIE3,T!/:'FB.ID8##"638Q[HG]0,FI,9XH^LN__I"J]:\6F9C&Q#!YQD+% MIEZ($VOI1CF]YB!<%N>D+X0Y^W]*Q4JCXF+/\- 883\2;-D>%@_%GK51W>[]S9U1T8M0XH,ISD0P8:"/*B:XIG.:L2Y5A M8.@C@T_;F*@\DDYCW8V%A6-*G^)I]6BBN_>()P\H23+*)P&C FMUQVG3&A,N92 MY9\9PPVTZ9#SO_]3QK_*VS#!E,3*PQ M*<83X;HG /\#6Y_!OK$W2J*>9,2+(NJ<51?[=0MKX!8QS&=(RD MC.Q#XLE::MGL3.!C3"UZ/]68L+ZG[@B^3AB_.[VH7-0_JA8=S@Z9V0DP?[PL MHFE1=GCHHZ('CN8PIC()U-+U?E"V)3O&-X.W93!@#,* M/U;8.(P%)IIS\+"=QH:>.KK)C-.<_6=2_]95;'+/%NYL8>J>U&^_SQ24M^8F MO=<8Z:W]O8'A*C#+^N2+()X.,^N#+\/!C*DW]ZKM23EWQ.5RX9UTF=-G/)ZT M/NBZ,PCM9='*T5 8_6OJGH M%E/)Q@Y[L#U[RMGJ+T5G].&L2:Y,8V0J8V<;W# .IN1RPH3)3-#-_NR7$)PS M+;] =I1PA3C#,&60B4O;G YL5^N=:(H>IYSQ>G;F-#0OM>W;0FB9?HR=U M^62HZAI?SWO?+_E/S:^?V3EL/QB.BL#7\'J8+6J M[O9AUN+"B<54,M4]3(.3B &^;GWNNE1]MI -O_!&B-G2OR]=.B6<)/RD9@J3 M8XI8?7/(1 @9J\S2YB*'"9_IO<*%"CO' MF1 6'JWIQPXM8 U_%9)P8CCLF$H$U-+M15_9XI M0$RHN?+0=-R?1;_Z30:*SD6C8T<8FJM2.TJ[Y7=R<'WR5?S9CF1E%!Q#@=B) MR*L)*/*6V>:> L#.3INK%YQUN>KI6-DV';D6S@HU8<#6K;#=,N:>*K/HUZ9Y M#_M[0W:\,W.&[X\WEY1W]JJ+![YG?1-%TUZ5"_89/_>'CDCZ>#2R9K"B(X[H MLS)F6C3?3ZK/X'=GX'>:^19/[]DW/6\8L_O9SK2X7;;9JI>L-F;%B?=K,3Y4 M[QE/ZC;K>X56Y/HB.#F>N5O2,Y<%V7"^KIDL>;O*X/VQ&;_:)1_OQT5+YLWOL/R>QKU1X=MG MJJNO/M%ERU]R^;&_]R'9EB' KQWD4GGNVH%X+L$3P[ 79[3FDN0OY<6[+9!P M6["[G=\0<.>[7HJA,F;T6'#MSV[)V'_<>)]JCGS0&+MQUO*X[[9T4WJ] &.4 MG)K.)N+: O+6J:N-Z5C4O8AP%&/W%NI52NO<]\V4975@*UR>WRF6ZB[0&=[R M#I2Y+U&=-[68@':<@:\'&%UW!KU.E:W:K\.M/G.#';0X&>+?O2T!=^\/OJV8 MP<6/ ;_UQXP3]=%E$D8?VYRZVY;MCR$_*QBOZ<98'9 '.O14ER7,RP\,?M+, MKG18O]S+P@BROV=-[QC95<5<8;(MLK/KON':WYB2 X]Q/Y?(+SIS8=]13:6/ MU#4Y'PVNOVK?P,?<'*8_;JO;@=[I[+D5_($< MT-YVP5 B1CEZ3@%'A/>V\0HL$5>GH3_0+I#SNV M+46,;^-:O3%Q>&W$C$WO_+YF!S+IJ,[/;F /T\7'3F#D"A5D9!K3"9E,3<;0 MSA6988X4?795_\14&9N:8QX*PETVGD/E7K48C8A_PQ)C4\<"PK> 8QR'C MQIWKB9G6SQC?I+8[3^<6TYLC9W_N!'+^H"E/LTO<(ML"M__C?.I,R/W8-8;G M#H.-@LL'BO4PFR+K<@.S8']O*6$/[IC->Z_:V("[V8 B!IXL;, )C[3@7++X MCL.)'/2" U;H+];B@XX5+SB\;;2_MZPC2BWW4-I^+[@[D4=YZ%-KRDXF@Q\U M]SP&U-&NG#_'\<)CSD;88#.^$7GAE#\NB1^<'0 M>#"GDR_'E5UWAF(.WR)L9A?IBU+2>9[QI%.31XX[]\X\5,WR/-QOKT86,2LN M/++17,?AZX.@_;TE[,*)X[H/;?(_=N(N1BYCB7&#=/1/W7!(R1N9OOF;]673 %'PGDL+USSE. M=4]^ST*[^(9T'D48C.5M_YN(WU.%C6EJ/#),X^\/9F; $^7BB X/V58Q^16; M/WLY&VMJ6S;;#,X*F.B>)3V?2WCN3F+I2["/WKPYF^SMIG?-NS X=*+=32)& M>;QZ"#??#-XM;T#^+LX8>G^/LZ^R76Y__U#,3&<:!%WQ(#*Z;1#QF;+(IXM\ M//=,WL?OX7:/Q..MZ6PB 0M".!-93'3@ M\+I_L.QG+MAAWH)#Y07I7Y+.7Y>W%_T;7MS M_F_6Z.KRFNL(3[)3EE[-_ZL'5EAH>:28V3C9$+;)@Q:W^%K"26IN2AHWA8ZY$K]3$+*7(?;)!OO]][- M:>><_)N)=4=/B;%*T7I"^JI)!)F*, 1M -<][]WG\_\Z\QP":O M0FT3A'Z==-HGU\<'BN6...'/\HVII;WPCV=N@3CK?F5Y1X6"YDRUN =3U:=T MR,&X?/5= HU$-HH[E(<)$X<'LK>-N!-?L>QM=\PU+S480EX(C2%D85J1 M$P4:R$*1T!!4%G(OEJNG.M>9;G&-14WQO9ONXWK&*\K&5N=JPBX0;[F\6P;X M\NXV&#&:)@OS7D'X2">>(U+Y+9.3'X[']%OAC\& TOO[0@RVBK]PS#*+S=F[ M%_[; \6V3?5NZKZ[L0WR2]%&)J6ZY;V/[&B:R@/DBZ2G#TKD@%]M;[N;/T;X M/W[72<\184H4S+-/\FH_JT46\TM2]IBD\:P2>LXKA('H5)L2A' L,X86F+K MK"E,&%#57%6C,$Z!N3MF$H6%L>*09_/V-JP0Y,%.P4X1:J=LY$6#!PT>M+QZ MT!8>0KTEOYF]5G6>Z!S%[":#%,2*(]:0O-=-3J2O]$8++R6+8$3#_L'^$6K_ M++?(UVTI:%/0II+0II+0G8(7 (SQ' CB.HRDEP7'8:L1VJ&9&KDL"LW_]8=4 MDV*8&:B_"XY?J\Z*ADA61)57.B2[5)!!]YWX).=9[2BC]4/J3)Y5XKO_SWO?+MPHD.3A16S7(=ERJYXGZ M83D>RG]2>F@%]V.05;FB?FB6AQ4 *T!T4B7M^E\6[L.]_U8.SM1*V+M%G*D! MI#I(OGL^A]:?4@E5Q@T9M/Y<43\TRT/KA]8O.JG$\_W?V 8O #VQU7%^ OUK M.%UQNN:*^F$Y'I9 4F9S"[X*R*I<43\TR\,2@"4@.JF2]O_WQA-%-7F0/Z^2 M/C*,X9.J:4XM^:)^!$P/6R,A M[/ L!](J7]0/R_&P-&!IB$XJ4>\I9'(_,$#',%\+SDM(\&!QUY)3 M69LKZH?E>)@%V#8YW#:@?MJICQI0,!720:ID+R6\B9Y<]ON7?RV;Z2DU;475 MB49'BGM58=+15%,EOA*UDXL.BFVX5#Q#A*? M#-QF74(<4(LL AX #X 'XM.%LL(C.$J6LE EY"NPM6L2GC'RBCP.$/! 1+L_ MZ.&!ZSC8V,F32KSKN+YA[!."/-@IV"E"[10$=L#I) JIQ',ZM4^..PL>)_N!FJ_>)OH\H;I%/Q^U MOYQ [ LH!/.WXDWW7?O[Y46?W/3^P]I*;[3@GXI'-.P?[!^A]L]R2WS=EH(R M!64J'U&RA>,+:CLOYES=B3S0X8C?TQV,%%7_[+R@BU'>B^(1/)!")Y3^+*@G M0WC:XTE*JCE_G:@3=5]D171)B"Z R,H5]<-R/-)LP"H0G53BN5A_\+=RADXL M1:,\R1_]/57M%S*F]H,Q]%D0.3AR#V LX.3-(_7#,CYL!>R>_.X>4#_MU$>( M!NR'=) JZ5N%^83@.;85&JA4F4I1CX,V*8['$R!LFQQN&U _[=2'=0#K(!VD M$NUV86UZD3XUQZKN%!3E]@0O,,I^&IF*;M,A#_>^5FU*.NHP]#&=^Z1*2*V# MU#K@ ? \O/A* G)0@=21!5Q5J\J+3>&>64!G"3@@\/V MSO+-W/+\?$M?2^? YUU#^J54^EJ%/?2%IWY8CL?U7$+ '4BUD$G+Q#67A"<^ M9%:Z63_ W=PJ R'J"Q,D\ML%*V/%(8]/)/(#WV#%X7<*XD#@BQ*%5$G[HMZG M[?-<4+;R3":F\:A:JJ$C:9^@ B]_*]YTCR%I'[@)*XY414+2/BA.PI J3G]0 M,%7JMG130^F$9'ZDX$L8O=-H^41$2 MGO007&EF_ AO\F EP$K(LGOU]G\=^HBU@#&0#E*)=V709[:!.IXH R='G^]%4 [.W8-J#0ZXQ(@OXR%# M615 @]$M/N#Y^83GC-P;"QEG(C*9Z:8,?**/(X-\$#61]M58C3IQH+7>JF#IK;A%5 M]ZI'K"KR;L69XP)5FCL>KTX2 "^MF%! :X6D.495F MC@^2L!)NJ=R:GOE;,=Q2X!NL&&ZIU/A:X);*E%M*I_:;3^I ,RSK,U%LVU3O MIK9RIU&GC:$/V,"FH6FL&5%UFYK4LBT4F!!45.9OQ9ON3A28 #=AQ9$J5R@P M 95+&%)%YS<*IF#UQA-%-;EVQ7-#C0QC^*1J&E%T?K-G*_I(Y3J58EDT'^FB M)(06PG&>1^J'YGR$I&/[Y'?[@/IIIS['[0$N&-(LZW'2)L7X ML!*P>_*[>T#]M%,?5@*LA'202K3[A;7I=<][WR\CS)R9^\SA!R%SVZU=4UIT MM;PR !*(@P@#V>?2,3]GAV M+[M?4Z+1X;QAOFB1_U*TD4FI;I$3PV"&?(=9YHH^H$72TP%H1_^Z'2NO-PX9$P5:VK2SY%D41-+'V-$_7-Q6;%+ M8C9HM2@UJO$/S(=:@QH.Y<29P;]$]]]J609S@#D6F:-2;#2B8XS@'H&T, Y. MH,WXJE:L598(C6D>BOQTVAYJD\?+ZUQ*CP'+,NQ8'*& M<(O%?FJM&"^ZF8O44UJ%1 I("Y!20-K-7&$;2Q/A082T3#^& D@"0%2K!=; M; )?^IV3\ZXSER]GO;_9YZ>4!\RQOQ'GO_:$6/:+1K\5QHHY4O5#IFH>273\ ME7B_>YISF7_DNYVXH_>&28\4[4EYL0I\J)_77JK[2F'6I7/)O&FU^;S?;USD =V@]'S5)-U0M$T=21 M_JV@T7O;^5;[:M;,MX#RQ'ZW /Z13P^77G_W*^*N)G][S&\C2/]R_=W%Q>7% MW-7%=??T\N*T=][K]'N7%^3P[8.+'Z3SU^7M1?^&7%UW_^Y=WMZ<_WM_[[I[ M=7G=[YZ1]I=;SX:X.O:MRC=E!O+7A46^6^,;%URY',CQ)Z?=KW_RY,/K7Q8WSVR>G^8$R<<_HS-TEN_.EC@D(KQGWEAGB/Y\?[V0EYJ+ M@F;C$YO)^^^]F]/..?EWMW--Y++\SO<8K%9KV.S[)+FS6)=:H+D.Y5/Y6*Y$6O2]N4QFRM3'KN0GH=(S<_R' M:5@6SV!\K]KD@ M@"'D=JBS@[<9]XL*<5'*E&RK<"VJCDV5- Y,MN&(21X&=M1+M1V\%@OW& SV M!>R+#%\BH%S[<0V^I%V3'"7,4LSPN&A("+< FT!T4B5] MYQ!QQ43QA4H+QRB.T5Q1/RS'0^-/"#BI@M@BR*I<43\TRT/GA\XO.JG$NP?H M#'Y/F0' +P$.3:HI/*4\OPH0[8%!'"*GC@<&.&1S1?VP' ^#("G@*A!5$%5Y MHGY8CHFB?EB.AQ6 ;9/#;0/JIYWZ 6R"C[4U6 :P#')Q4; VH9AK2A@3 M6QVK_SAO"D*?QV(5Y]O%((M7HC$O2;A#:)$O\@I\A&==#FN-9(,'HMG\(0J[ MBLX8.#26\DW(#$GIYXN\ H]# SP0S>:/MOXJ3&>8SOFY5-LD\W9G^-^IQ0/M M1OZ<7VL+FAU<&/I<1;,Q5:RI2:/)$R:6XI1446NY692CR'^UR0*%3"$CY$F: M%#=$E P-S) %9I#KQ4I92KS(?7JX!>?,:F:JE(L5.;K\?NEGEEQS0T2)Z< , M66 &IH)6I>3/F;#Y\Y[7&%?R&N,JO"LJ]O-HQ7C1S5RDGM(J&5) 6H"4 M)N MYHF*J=1C%K3W]&&<>@P!$D 2 J18BT'B7@GW2CD,R72LL1NJ:>P/13*B.C45 MS7G$I0S'JJY:-J_C^D@)?9Y0W:)6'JO*-(IEGDLR=-?"ND[2@8-4K$NH*I,X M#'*M6*U$4(AD[0,P05'*EFRK%>6JC$V5- Y,MC5QQ"0.@UPIUFK17:*@J@PL M$M%)M837=FI_],83135YM1ABW).180R?5$WS\DC8BCY2[S1*%,NBN4@G=R 7 MRU+HO*V?!75;"4]^/,].._.O$WVB;HW,"+!&Z"QSHD(D/.TAO5+-^0&LAL\? M:W*P&F UY.0>8UD.:F5LF'94F212(("J]3+.WL2D/ZRVQ&A?:<:PDV M0KI%5[6"[9,8\:5:R&2"('YPXLM-&49"FC5?& D9NUK(2WG+ [G:@MQ/[- % MZ9/C^UCS8(H+388D%[9/4L1')%+"K!\R$ #V NR%E) JZ4L%U+]T-%6XYG#6 MYI'ZH3D?=@*V3WZW#ZB?=NH',!5@*EHJBG.G8,R&)A317.O(BQJVYKSMB'\+81819=V,0B*XZYD$? > \$)\R ME!4>P5&RE(4.*B%CT]8N2E0S$T($!PEX(%HI$&EE%-CB'O,Y*^PMO M>DS&5+&F)HVF[(I8RE=B%5(KQ6H=]7(%.X23*YYBJYT%9D@U,[!SIB+'7DDMF!=@BW)$SVN, M+WF-\15=H5B4G49%8Z%)"Y!20-K-?%>XHLL0QJG'$" !)"% BE0)Q4T4;J(2 MOHE*XE48L[TN)Y3?&NDCHNH#8TS) ;\.BN;^)]I8\QA+(E/>>**H)G\@1HQ[,C*,X9.J:5X:.UO11^J=1HEB6307Z:XC*$"^ MB6!.\W& I]U9HWX$3+_6MA -E*P(K/ 5I82#1GB:0UJEF>.#F NP$V GY.D& MPGW7XJ2-(+9!Z.^I:K\0JI@Z:VLQRX!TQM14+6-J#N@)-49 ML )@!21/JJ2O!_JFHEOWACEV-'Q%(P/#LLE8T=DD^*5!#@[41BMT$1L(]ZV) M#J?F[FDNQ5KV04!(LB*BJ@W<5^Z"C_2>FA%=R/05;EBOJA61Y6 *P MT4F5M.M_6;@/]_[GX7%P!4^#$Y#J(/GN^1Q:?THE5!DW9-#Z.*TS17UPW(\+ -L MFQQN&U _[=0/8"5\[+6%K0!;(9,W!*YE8$QL=9R?)\ U^-U2*=9QJ";%\; $ M$@).:N$6$[(J5]0/S?*X(X#>+SJI1+LC6%M:\)2:MJ+J1*,CQ:TX8-+15%.< M.P1E,#"GBN9>+5C4MC7G97'X6X40=4T#RXUMRBM&/TA\WI <5N0$#X 'P .; MZD59X1$<)4M9J!(R.'/MFH1GC+PBCP,$/!#1[H^T8CBL;EC=.;IM6W^ GGBU M/.B0&(LUQ=O?+R_ZL^Z?'E2;'EH394"/=./)5":%XX,+0S_DA., 2MX*_2Q:,5YT,Q>II[0*AA20%B"E@+2;>:%PN98AC%./(4 "2$* M%*D2&OL++C2)OTFR-S2%XQ^F85EDK)@C52<'_#;E\WI)(6XLM5PNA4[)]4E0 M@2D\\:5R*72I21 _*.=+I=!%]$#\H,27P?E)BIW0[UM!_*"<7RF%+COP"9IL M!IJT!7OA4WB++1KYE=PP<44IWJ?E4NB2@!"24(S31WRF&(=^4@[B!U>,(7:@ M&.>0^$PQ#EW@$HIQ%IHD[>*]H9K&/BV2$=6IZ3UF5X9C55*W M< N8Y'$;J;T-Q3>M303V"%NA=.)\NI"E>BET10E(U8#$;T1[S0;:;Z?*P7V? M&/$;T*,3E#J0^ E*'>C1:"* _GR-37+?)SPS>W5>TYJUCY])8_4M-6!HATJ MFCK2C_@0O%0N^T*JMV0YVBL=B,-MQ"%HGR#?P_A(BO81QU>"]EO)' 2O),?W MD9H>T'[3VD1@+[*QJ!B'< SG3IFNP*^3&.UE*!50Z')(^RK\F9 Y.:1]+=IX M&$E$=*[BC5">MQP(L[L6;T>:!-.0'V]^COJ6J_$*J8.OO= M(@>:85F?"5/T.F-JJI8Q-0?TA)HCUL/<4%M\L4A,:DWH@(<<:"\ETOYRY9#V MK/E!>KP/O_ MR.:GWT1\OY7X'\ZIWU?WXK2.7RIU=V.NU>]+O7O /"9L.Z M\>;79K-]57O5H?UPU"S55+U ')2^%31Z;SO?6LHIY;6,(DFK..7DN'U[?-/] M\1>;&;GNGEY>G/;.>YU^[_*"<#V;]"\9NU\X.C>C[>VQF[?/H?$2'JOP@1>F M]FYF;WOTRMU1?!>0T^XYMUQ.>Q<_OA7*!>?WJ\[9V>SW.7JZ^5Z!E@ M& CGG:N;[M'LAPTLF!DZ P<,3F>769Q-ZFUY;_1F]9,GR5[_LB@%9O/\-"?R M/OXY)YUM[420EYNYLL_,E>H[N>79_'Q<=98M$O!M!;5%#EQQDE3X27)GF$-J MSCZ22F6VH99D'/W>NSGMG)-_=SO71"[+TJ;I-H%!=!CT'TQ*R9BMZ<$B5!^R M@^W">*3C.VJZ4ZN4BQR<,CGX7^ESK BM\!?%UR2UG%")@1%N=95I-0[ =R;_ MP#^K5?_>V$R=LC9I&3H5<[RK]T^UQSO5F19IZ(J6TC6<&N;$8)HP?3=_%URF MR;J?7=H/U-Q2%Y=GCDFAR?%+T49,MNE6^^3Z^,0P;.<'/STZFJ8J^H 69[@/ M2DOA]DRAF<*5#8&7L)N]XEJ6X#V?399E,=,LXY M.IQ]N-X O>%AWER]C]WHK_B-_C]#=K-8!L\W0;E1E.K!G^)YT]QN2PM#B&I1 M;@9W/J5[[0=2\-AE;UZ?@[C=A"& ?Q=4I&*U$MP%[.<$:+GI%O%,"W!SGTY, MXUZU7]^YN]ZA758L)_+2+]TIJG$"0:J" MD+R_1J _?R4K+_RV%6/>?883YL,O,U96( HFE 297KZ&!0Q"# L8A!@6,.QV MV,Q9([EW2+5/%BM=>%<:6[]&V]][RU.6M7N0!GS=N ?!/ASGR.;;JJQ+)J/; MJL5& V:,CR";/+9Q_VW5(M?P\T$X_[]@OGD?2Z,%LQ'>RC4G5V?P>ZI:*H^= M.S2IFW)!&1NFK?[C!-2E/;[BH!$\:W,6XN<.I. UI[*P?D19'+1"O[5"^%QV M!'[FXZ7K^0Z8/I"#)^;.Q/JEX$F"L['^JO:T&Z,]?[>%E'6)*-!UM5B7:[A1M079%VN@AP^_JB#&O[K\EHCO+U+3?7\IETNAKS _I3E 0:Z4 M0E]N!2) ,A).&+)+T9(]<\(V9Z)UH3RU)V-#E:=.O6 ._*NJDA-J#EC__#F^I6B^,I/IELY2HQ3Z]66ZI;,5P*8I3+\I#/T-+MRB/V!2'*-^4[T*_=\VT*,^]HOV6 M"]'M='_/4YYO;J_>0]RL??I*'JEIJP-%.U0T=:0?.3=@;'.S+^PT%"V6EV0) M*9RBK#\I?U"^I;0,(0U]>XF^;2S(YE"NZIS*\YS[MQ,R._(MSRNET#FDWLES MUM67?N?DO.N73#[!)/FED%\P;?!$(9!H((N:H^6Y U8(+XL\*(^4W%&J$];C M8.H^T*;/ VW*";"_MYA*UB ^RJTEQ+A HZ1=AE% MZ[LBJ.P1M*=S4E"+#%@CA:NI8U9T$5-9LIE_.>G\SCCAE9PHUV0?$^:\] M(9;]HM%YEN#'S<("^$>^<_2.WALF.T>U)^7%*O#^?[+CMO^ L-FP;KSYM=EL7\\K=6@_'#5+ M-54O$&?YWPK\N'2^M12!]2PM2:N?W;1OCV^Z/_YB,R/7W=/+B]/>>:_3[UU> M$'Y DOXEVY@7SF'):'M[/'M)X^<&WT R&VAA:N]FY@\]=/8^WZ_DM'O.=9O3 MWL6/;X5RP?G]JG-V-OM]CIXGE]=GW6OG'#(3SSM5-]VCVPP9:SPR= M@0,&I[/++(XX\823-WJ]^-UK;PS;VVN*=7:!$RUR*\2&GO(^?]J;WX_I3)R>^JQ0XD\L*.3T*9 ML3(DG>F(':SNO"I2DI>NM-YPSXU:S@US(G!S [Z;OYW)F_+S89+^X&: M@J_IEZ*-3&8I69R33@S#=G[P+ZJC::JB#VAQ!MZ@E"+,L$VP383:)IZ/968? M02?(V$6K[+K5;G@D2HQ.1=GO5/PS9#>+>3Y]?"N5&\5&.7A$A3?/E%)"JA;E M$!59TKWXD.E>Y55N[Q210)*E8JL9_*8^Y0PP)P>JQ5HEKY20:L5:-:^+AQQ@ M"QRK[&0 .H50YA-:K>LP\<)]23TSC7K7GBOO&S>T1)7Q:RO2L;UDN M5LIR!%WO(#'8;BA2*38:X:H<9XP@X X_,>KLF&B"(CZ*5(IU"13Q483IT=5W MEUQY)@@DB)\8S:)4"U"ZI5"\<+ \*1,7\T.8R[[#[H(AP&CF_'CRS!*1^JF4>*)!7WJ_GU#T/C@<% M(N)]*'H9<]O=V(9)R5 9LT'=1"6J_DAU]ND+X=E"=OL M'[Q^9JJ7#7X'!:)A_37:W?-7LC+I6(@*Y9);H7PA<\V,2@F6B@\SL7P-"QB$ M&!8P"#$L8!!B6, @Q+" 08AA 8,0PP*&W0X+AW7&@A3:)V^UGT;^W$5;UWWR M%4[-0O8%N5B3*\A',9_OJ Z"(%O)'!84\>4[:LHU4&0NWU$3&=,@ M0580HUFL2I%+$"BL\2NL.[C4J+C&R="8WFE4*",QU,SR-BZ0$&5<("'*N$!" ME'&!A"CC @E1Q@42HHP+)'8^+HS'S(?GMT^.;ZBFL3\4R8CJU%0TK]#[6-55 MR^;UY!\IH<\3JEO4RE))!ZE5K%3@LO51I%9LUG'GX_?)5<$??G+4BM4*[L 6 M9$BY\?^W][6];>-*V]\7Z'\@LJQ>3GTB^43G'J)(U%"U=3D)I%B#1K.)85;MTH5 (@=I"T"Q=00P2 GX M,2]8@]K[+1?5#/:&49PJ762DXE;;1JO"2K-TKP"EUX]70<4U_%!0<6VS]T#% MKI:N.*,T Z $*C6YAT(8A)JY!_7L\5JIE6^5I+3FJ]A-P^W?K"&ZR>MOVH9; M?W:K=/$MM1G0-ML96#';]JTX+:EA,5A^1KH"%6X?5G$P%. MS7 +R"G?.E-I!L#_53'<#>#(/0;#"-3,_:=K:[&*;?;A%YH?', >,%T"P %P M *W&J#]"SQ&H2ZNQ2MUL#Q"T'SA@^AZHV"VSHP#8 N" [$T &U S/^ ICU// M#UG !Y.Z-3$?W =>[@CT^OWXW@O&_L&$IVF07PU4U#4(;0 .@ /@0,4U^X(8 M) 63O\M6F0! PFR@($$6>[H5JP1A75AQ#)[:T6]@^,PU;:TUX[HL,061G M1HO8TMJUZJ1%:E:S@7@&]4>.R%W;T;^Q;?F^MFJN6TH_6S67CI0T*7ULU5PZ MP"_?O53-=0-Y2]JV]18S)O&,6I MTM6)W6KIFHQJ+KQ9NBF/FNN&SG=-]>NZMJ$R;U=+5QA3<^'8[#5)?GP8>)KY M]&YB+TR^1O$P-]Z\(&\RRX9>*":1>?H4%?=VZ6Z;:B[<+M]H6LV%E^^MJ.:Z MF[:A!Q<)5?057;AKJ(?64./5=>3@#=-->]_<1?=#CXWBZ,%/E/7$M0T]G.., M"@Z8*ONVBUN&AHH\."!+^&'?:>::6Q1IS;QSBF90.&U#E;RAR[8-]40:&UYT MVH9ZY&##&"KQ;A77YD@^0L\U=YU&,6>WWE 032:)L0\\S'NZ9M57 ')#. 5B!FCGPQC9?-$K]H=+)$75DQD''&+ECS^OWXWLO&/O[$IZF09Y3 MH:BK#WH!' 'P '7T(OX0!X/1;]N@Q&W(ON8^Y'ET+LW9)-MIJ_6"(O*Y: M6K"C8K?096SAMG%EM;;4@B%UJY7UW !#I@QIUF7U^-2"'16[+JN[ITYZI&'5 M6M)?O[!CMV_'[B#6@;[U6M %$E3H @DJ=($$%;I @@I=($&%+I"@0A=([)SN MT1[NIT_F\/S?39F'4CW&4)).7"ZMDH= WVW>\;N/J MLU,]+%V(_K7*=[^=QF'ICFD;,6 _:HT,V^T]L9T, YS#TNFH:C.@?5BZEB@V MWOIL=P]+UW4LLAVFC?;9T$\7Q@9%JZ?,+3$E-T[UL'0E7+45-BRE/5E*AAL* MSF'IDHQJ,Z M]Y6-C;>JI23U: Q+23,GT#4/ O&MQ08\Y/&D4(QW._1#/TFS MF_4/G/'O(QXF/&$C'O=YF+(T8HD7B"]4]AK93<-MH9I]6+IF %0R;/"U-UYK M3Z8 %0:(0TCIVHW8>.O+75ON(02VD#E>HZ24F62:F\EN&/Z*<^K0\/NQ+*I& MRYTXTQCN9ZOMB0'&;SR85I0?V;>;J?=4IF'VOM'UYT_/ 6[57__.'GB<^GTO M>.L%_B!\E]\GM8]^$W^@Z!XQ/0)0L27HYC=0SFLSOFJXNZ6V)SSJ, MF;WK7+GJ'A:1.^TET'_?Y"8\'8H094FO\H<5BGHQX/XN)!8^'+$M!SEA[UOU+\/F4ARF/ MQ1"SC.;#9WS.OBI88U_XUR@6UECPS7M,#K+Q_Q!V_@K_N MP73(W*A[]VL[_^^ _=T]N_GC_8%=K;Y^$J?3\\N;\ZML "9F(X:9S.](S/;) MX/)OT[MWK<.Z'QZP'*7W!P'_FN9_M5!27A84VUXF*2?'1Y^/K\\__BEFQJ[. M3WN7I]V+;N>FV[MDF87';GI"W"]S:T_P]O/QN#Y8SN,%,F8+:?]];FK/9E;, M%L]W5+8+V.GY168SGW8O/[X_J![D/W_JG)U-?Y[AYTGOZNS\*O]^,H?Q-V\% M"!>=3]?G[Z8?5K"=I^CT?MNM)7?^&_^,2/,Z]KSV^IZ]<,:?J5']6DY Z,^QZ26;'@K7H^7T0,??N'Q>!IN MU1)*9:]^ M'!\0.M$S='*=7;/=E2?K/W)=6479=1J6[9:^.:HH(URKV2SM2U5T[2KVKY7, M G$ :=NE8PF*+GY&"30MIU8ZJ*0H(VI6M:U,%V\H >GO -MRW=*W!)>Y+F#V MJ7R'6!P.QB4+1W'TU4^?DL_7/5)M)%$G/^1]EEYYF<_;+#7M&OH*%=JU6=4& M&#+3: EMEIXQI2%.#&CK-]NNS0%#9O2(W6J!(3\8@F9^Q69^5M66OEU@=VKO M;KR)O3#Y&L7#29R"]:,D94,O%),8\C#=U>$+QT_)IT]5' \ 'L!CV9!W<&"_ MH@];3S,?XT7W0R_S+S[XB;#L%!5MJ'5#E1HX8*KL.Z63S=5<-R0>') D^[#E MM/?;=?K_W@O#+G/:O8WY.#LR<]WM[.H@2<%7;MU0>>" J;+O*G-#$A(/#I"4 M?1AZFCGMKM,HYBP:I?[0_U\>DE53OK'#P0%P !Q0)O\!P(,#%$7_!0OO^^]L M:2F*0J+T7&HT6UC2:9)\G9>MRC*OO\]G7O](GEX/$2(3,XLL8"!!%C"0( L8 M2) %#"3( @829 $#";* 8;=DX;36_G;"T# $R?$_9TK#:M4<2,E,"D3CJE9F8:72!!A2Z0H$(72%"A"R2HT 425.@""2IT@<3.Z<)EK]D] M9!('YAL0$/>>P%DRZ)0S_TDS1KQOC &?\^XF'"$YT*U-:L5K4-[\B, M#]Z&=[4H(? DSOJ:&]@O,PJDV4;,:E:!8,O,Q*OJX$91@;3EOW!AD6I_B611 MB0MO&,6ITIF1E:S,>[EIO7GY!$QX_4[IU&>EUX_$J$J[=<I26@4KXUG-KK MM\U>/S1 I5VZY$U1 F +:N:=U+,I0:51NA.BTGJO8E?-7K_9AJ_Q!Y]ZZ8*^ M:J^_5C-[_;94HT?!]=M2WW^P^HST "I@:$":B9XT^7\K<5LX]ZT//@@.%;H.(@R&GV!@ ').^!%ZP] ME,*E4^*+%EG 0((L8"!!%C"0( L82) %#"3( @829 '#;LG"@:W]'89B*=QD MG91[PTOEUJPZTBB+#&DWD85=E ^D8,_DV-9;$(\Y]0&&%-5'"]JT*!_@QHSZ M:%2EUY/>C[\>I<6TH LDJ- %$E3H @DJ=($$%;I @@I=($&%+I#8.5TX\C6[ MB2X.LKT1SWSRX8#Y83\:'! DNS#!-3,#:EG#X3RE4#57'?YU@=JKAOZO7S+ S777;[5 M@9KK+M_B0,UU8Z>7;VT 2\X,9YZ>70[*-SE0<]VVH=X+0TU:4PV;>ND*MFJN MNWSS C777;YI@:+KEK1PV'&:>>0NNA]Z;!1'#WZBK/_--=16P>D4'#!5]AU# M7^20>'! DNS#EM/>)Z=9QRG;U(ACZ38K:BX;JMYV#'742(H[*;=NB+RAND[2 ME0H8=9HYZ'3I(65H@ GZ'!PP5/1=0Q,_(/#@@"39?\&:0X\H.K7O:9$%#"3( M @829 $#";* @019P$""+& @018P[)8L'-3:WSHH]HB*EE2=-+P=E&VYU1H* MJ_U@2*L);A1K5.LIMVT^XC8N[CGU8^KK^:Y5O M+CNMP]))UALQ8#^*C@S;G!^-9B Q[RV N8%]XR[W;HAWZ29K? 'SCCWT<\3'C"1CSN\S#- M^KXF7B"^4-EK9+=,/[PV#DL7[(*27E_NVH8;!W;3< 8X]3TQP/"-UY)[+(%U MI*O7*"EE%)GF9A+ZO'3#+=7U^7[\'<;K<[/#;_:^#'@J#'!J>W)P&[[QFC"D M2#]"S\W4>RHI,'O?Z/KSI^>0M^JO?V\]0)_$+[+;YB*S2[^0-%= MXQIN)>WKKHC9NMK=4R"&SOK--I%<[#KU=3T,)%T]3=&\753">620+54S/8)P M6+J%)+3Z!E*WG]MD=-9OMBU5QZ6FO4B=5"]O_NH70_UVTSFY."\FWA;R;FTG M2[)=D'<[\^)?8!H()F_T&F;S#I)D$G-:8B$H3(S.D,=^$MW'?7["XX$888;4&G]HL9@G M(][/ F+!XR'+LHTSUIYU_Q)\/N5ARF/Q!?CZ_./?XJ9L:OST][E:?>BV[GI]BY99N&QFYX0]\O< MVA.\_7P\KER5\WB!C.5".S>U9S,K)H;G.RK;!>ST_"*SD$^[EQ_?'U0/\I\_ M=<[.IC_/\/.D=W5V?I5_/YG#^)NW H2+SJ?K\W?3#RO8SE-T^CD8&9_'PI)O MTLF6GU!OM%Y/=-C3;^:UP'2>KV>4W<\_8S ,MN3S=H^)J[_P7WSBQPG7M>>W MU'3FDY(1$U60UWU.Y^L^"Y7TH7M]VKE@_YQWKIA3=:H_JY9'G1EVO20S;NYB MSME0S/PN83R\%:_'/[W'\0QG)JGMKFJT4AECCD:R_[[,UXY(C<-8WK[ +KKMQ$_Y'K)RK*K=.T MW'IIMY&BC'"M:K6THU;1M:O8Q50V_%7+;90.^BNZ^!DET+#:#7.50*U:.D:H MZ-JA!'(ET"Q]-WJ99P!FGRRS;Q]&GC@8C$O_C>+HJY\^)7&O>VS92*).?LC[ M++WR,B_&KEM.$]V&"@QIM-"QK,".Z9M!"DW< MM&!(RVV!'5 D+[YO+->1_L:!!:J]X_$F]L+D:Q0/)P$!UH^2E V]4$QBR,-T M5\9Z_&B^Z&7 MN1T?_$28>6J*N%.Z]H6:ZX9R P=,E?W2V:9J+AL"#P[($7U88.CW MW]G2NFN%VJ5LMD(H6UB]=%)?**_0FA47^CY?7&B*\[H%Y(E,S"RR@($$6IL-BD6F2O0UTZ$N1MUR MFPX*J!0+4Z%.%^K)O"PF5K6..DQSA:FP DSHREIJ9:72!!!6Z0((*72!!A2Z0H$(72%"A"R2HT 42.Z>+ MPZ/VF1)')\?7/ C$+RPVX"&/O6#2:WWHAWZ29BW='SCCWT<\3'BB4R>.FM5N M5^&8^\$0QVJY<-P6/=EH.%'@1M-JH57+K )INHC\%!C2;J #1]&A#_4Q$Q9L M-EV$-X@_LH"A.[5'N\.1Y\=9/PT6?66#*+K]Y@?!I(1+ZH4#/SNP>$G"5:W: M5W&E%B!7;_VVU6Z4+M*K- N0RE=QK&H5G1@,%P*[#@F !,B3 %B#VOLK%Y5P M]H91G"I=YZ72+%W05FE-6+%1Y,SP-T&[9K0$0 .8O7YH ,D: +:@9IY!/?OO M5AS#?6&5\@V[U%Z_;;8;K.)631< TQG0-OOP5S$O@.O'^5']NWUT[63&^Z^F![O M =,WP.E[3XUEPW!!P?DB#ZL/>U=?;ITZ8&A!%TA0H0LDJ- %$E3H @DJ=($$ M%;I @@I=(+%SNC@\:I\K<71RW!OQ+.P1#I@?]J,A9Y4L2?:-3FW;Z@Z:#!78 M47$LNRXKKO-TN58'QDCKWJ855VRKT9+EF=2),:UJ$VJE*">NK.BH3E)2D=;3 M32>N-*K27\DP5S6[MJ-_8[?R?=W47+>4?FYJ+AT)?5+ZN*FY=(!?OGZ/FNL& M\I*0AY6GO5-R?%<[L_L2ED:,_WOOIX^,>W$HGDV$[<Q.-W3=V.F2=CHL.>W=>WIVY970E%?-A;NE*_2JN>[R37C57+=; MOB2SF@NWJZ7[;JFY\+:A,5M#%;HC2;/!E-/,*7?1_=!CHSAZ\!-E77".H9L: M!U1PP%39A_?94($'!^2(/BPY[9URBP*NF5].T<2*AJ%Q)U-]4F8NNV&H0\HV M-&W*4*5FJ)0[B*B2?&3?;KAQ?]M;;RB()I-LV <>BF\?65:ZA2MJLS4-#3/@ ME H.F"K[E=+WQ91._8#@@P-RMP"L/>U==6/[+QJE_E#I; A3[Q%!Y8$#ILJ^ MH68N!!X<0/D3DH^\P- M-?1!.UCER0(&$F0! PFR@($$6;;G9_RM\G(Z_-W8?0M]D8' MQY7+*'R;]?0Y^BU[])@-N9?)2DU6 W:= MN-)LHSU6@1VV5:VCL4^!(0Z84>P1)HL=.JD0L6>JLE0K&OKH%>M VU'1^T3(<:(/_^WW$[_@[[6+&C],8Z29/(J9Y4L\/QF^V[NK>3JM ]+UQ=ZK7+F@N,8.BU5/F M3IZ*&P=O+$>NYH#"7E7N2I.QL;;Y! B=>/!%C+':Y24,I., MO'MD&- PG %P,^UKXTGU[\*TTLS-U'LJBC%[W^CZ M\Z?G +?JKW]G#SQ._;X7O/4"?Q"^RTADS=/$'ZBZ1PP_]E>:]F'I$JMOH)S7 M9WRCO)]O,[Y3X<"^@KY4UE]QRS, .V\3E8_@&^5'"#N:.7,9OWGR23 -02:R%A=]X#9U\X#YD8L7\?>-EC M_'L_N,\8\.H7_N^]GSXR[L6A^#F9%BD5AD9GR&,_B>[C/C_A\4",,$-JC3^T M6,R3$>]GT;'@\9!EJ=\9:\^Z?PD^G_(PY;'X@N7_'XU8DCX&?);1?/B,S]E7 M!9OL"_\:Q<(F"[YYC\E!-OX?PCKN_E?PUSV8#IF;=N]^;>?_';"_NV]'MW'1[ERRS\]A-3XC[ M96[S"=Y^/A[79?^''R M=>WY+36=^:1^QT05Y&7,T_DRYD(E?>A>GW8NV#_GG2OF5.WVSVI!4F>&72_) MC)N[F',V%#._2Q@/;\7K\3)ZX,,O/!Y/PZU:&9=:K/)_]@9EO'63;HM).V]4QM$QHXG][P4!LE3#))G@216G^H3CS M3A#X7MCGUA2-_B%1$"#/D&=Y\CPY*4_M<40D](Q(7&=7G5/*?:,X^NJG3SG898\8 M+Q%]DO"?$EI'RL6@#:OJ[*\O' D6V);M[J^!$PT6F+W\IF4W#)< H0?:TMM3 MJ<4"H0=:ADM!9>^=VTBPH6DY3>G]#6$':N^JNXF],/D:Q<.)[YSUHR1E0R\4 MDQCR,-W5"=#@ Z LUXXJAWU #:@!]:I0ET[# ]:&80VK33/OW47W0R_SW#WX MB;#15)%FMW1U!V@N< #23FVEI=.3(=3@@%G"#HM,>S]:I__OO3#/,B?:VYB/ M4^9 NTZCF+-HE/I# M_W]YH!-[&AP !\ !9=YL,.,@[!!V6'&TK+@B0[__SI:6:"@4.F*SY838PE)' MD\3DO)Q3EI7\?3XK>2IOZ]:<)#(QL\@"!A)D 0,)LH"!!%G 0((L8"!!%C"0 M( L8=DL69T3M+V8Z_!)S44:[4 MS$RC"R2HT 425.@""2IT@005ND"""ET@084ND-@Y71P>->P%D_:(0S_TDS3KPOC &?\^XF'"$[6+\]:L5K5JMF?-MJIUPUE0,SS* M4+=:;<-9(!2!;7AIVG;+\!B#:_CZA1J0'VZ&?:C]G95%Q42\812G&V6OKB5I M4A-Y*LU&6T% M(\U(]YI2M7HKY?M80\UMI.; ?.D?H\K;NS'L0@I!P>TD7H8=)IYW ^ M\(2!]\B\?C^^]X(D_S[A:1KD,55UG'0V7@)X"1CW$MB3U)L79864@P/:2#V, M/2TJ)J'VK?)D 0,)LH"!!%G 0((L8"!!%C"0( L82) %#+LEBS.B9AO5UQ9$J"Z.J@[TD4!EJ)F-UC&UU?RM%261HS_>^^GCXQ[ M<2B>382ER#I#'OM)=!_W^0F/!UR96B6UTOD]ZZT4R5S@@#G2OK^5EJ[% J$& M!\P2=IAMVCOX=.FX5;[AEBHK+5_-'VI<%:PE].%19:GE&VNILM+R+5BP@57! M6M8&AB6FF0--EPY:I5N0*+-0F%W&:&W'&%ND?#$K55::91%B_YJQ?^MR+&P8 M7=J[ORZZ'WIL%$WQ?[=C5#:D&!Y27=IAGVKO0U.U*ZI3NV -]!@Y MVJFMU$6H#_O:F'TM2=IAJ6GF2-.ZQVCY9HM0<. I)W<2I%\C7UMSKZ6(^TP MW;9ONJ&'*,W>2+3( @829 $#";* @019P$""+& @018PD" +&'9+%F=$[2]B M%+N*1DN*=AO70#0K9VIX\T3;],YYJ/0]W0L-Q_!>JH(%5VW/1F M][#T;?K7:J4/.*W#TD749"QY/\ILEXRN'99.LE5-MMS#TA5@5%MRZ[!TI5%L MI]6V4^F$QB*C89AH=FQ\NL8V*-HC9>ZN*;(QW,/2Y?344[JP87:D=$NWHE)- MMESSEMP^+-W[ MMIM>TDU3Z&#:.]<^6:!X'XUF(#'O)X4I/'NQWZH9^DV6W] M!\[X]Q$/$YZP$8_[/$Q9&K'$"\07:GEC[-9AZ7YIJJG>!HTE:Z]Z[3:-<_IN MMY-QE@P1GYL)VPF6#.5'R'ACDE(&C/[N&Z&EI?HU%5BR4Z<1=3-!2Y-X'>YR MR4WSO*$N#93UWTXMN7H+1H_V[IO>4TF%V?LQUY\_/8>\57_].WO@<>KWO>"M M%_B#\%U&XEAL;_$'RNR3&HWHS"Y5,#3PCB3+-(]&S3BW%1'M8DLIG&#.Z M>G"B>1NFA%-&:[NG;MS1T\7%@1U)EFGW:NLTK( =KK@!I^B.)$MJQ#U_38NA M?KOIG%R<%]-="]FNMI.EMB[(=IUY22]XC0NV;O3*9/..AV02=UGR3D_8G?? MV1?.0R9&[-^/>ZCS[_W@/F/ JU_XO_=^^LBX%X?BYV1:&U*8 YTAC_TDNH_[ M_(3' S'"#*DU_M!B,4]&O)\%A8+'0Y;E^&:L/>O^)?A\RL.4Q^(+EO]_-&)) M^ACP64;SX3,^9U\5+*O=K M.__O@/W=/;OYX_V!7:V^?A*GT_/+F_.K; F9B.&FL!RE]PGO=3]?G[Z8? M5K!SI^CT?M M'NE6?\6__#Y].HVZ]OR6FLY\4JAAH@KR>M+I?#UIH9(^=*]/.Q?LG_/.%7.J M=OMG1?^H,\.NEV3&S5W,.1N*F=\EC(>WXO7XI_.3JY.KY.A?642,2P[-3&I,;_=K,!PKSG MNA<4?T%TOJ=1/(J$L\&[>Q?,_)8>9;S!:D%NG8=7MTO%G11GA6BU;3L]X]=:N M8I]=V?!7+=>E*H%DM?1U%T;5#"1P[;:M9ER/["]P#,/M4 MOBTB#@;C.G"C./KJIT^9Q^L>6S9L)?(D[[/TRLN\&+MNM6K[ZX!$D"&V9=NR MNN%HP9#]]48BR(R&U6[(:IVF!4/J5J,."9G5']46&/*#(5/;4@I'-G48$N1+ MPVK*5R4P/;7W.-[$7IA\C>+A)!S ^E&2LJ$7BDD,>9CNZOR%$ZA<#MBE[U>K MN6X@#^1-15X9IS. IP@\K#W-'(T7W0^]S,GXX"?"ME-3M!UE@BA0:N 9%_& MNAO*!(TA\> 2=F'+:>]YZ[3__=>&':9V^YMS,=)B)GS;F?W!R6_[)2Y,@>5 M!PY ]J6X*N&Q,E3BP0%)L@]#3S.GW74:Q9Q%H]0?^O_+@[**RC=4NYF*#1PP M5/1+US=3<]F0=W! CNC#EMN^+5=DZ/??V=)R&8624VRVL!-;6'1JDA&>%];* MTL&_SZ>#3\6N9(W.?4W,++* @019P$""+& @018PD" +&$B0!0PDR *&W9+% M&5'[BQU')S\:2@R*A0+*=/C4(,6Q;K7:2 Z>30YV73 $Q046,J-I51V4GIC1 M'TT7U1;FBI.@6@N*"ZQ07*!5DZY;8UPQZ>6V^C^2\!)G1Y+S!.(7%AOPD,=> M,.F-.?1#/TFS%IP/G/'O(QXF/-&I:'+-:E7AERPPI-UN@QV%J$8-W)B) H(A M<^JC70=#BF&-:AV!K^*6 3=F@AG5JO3W"^Q1[:_E=(*/R^B$!DB4 ]J%F M_LI%U?>\812G2A=MJ;0Q2F=R:_T^J'W*W:U:;0(5)HML]>?>9<-7C]4 M@% !4M^"L/VT]PWJV46M4C/[%%PQ^TV(-T&E7KJ4G](24+'+MR!1FP$UP\_# MILM_$Y8@Y4@$5[L%1J9NM[F'Q@ .F[X%*W6S_)W9 Q>P82*4!FX_R(_2\ M?[JT[*C4X/ R6_6# Z;O@4K;;)"Y+\^X2G:9!'@%7U",(98+8N! >P!0P7 ' ')#. 1B% MVS<*T>N-9@\+6F0! PFR@($$6* MO=Z2=>J?&MX+KF;5&VA=5*R9VFB ':B9NI@;=:M>1V^\6?7AHL9P47W8J!%: MW##8+;/JH]I"Q53BC^PG (+&&5K0!1)4Z ()*G2!!!6Z0((*72!!A2Z0H$(7 M2.R<+@Z/FJ54')T<]T8\"W*$ ^:'_6C(626(DN2-3IW>;*OJH%53D2$VO+ % M=E2DA2V>4@XTX(IMV0[Z(Q88TK*A1(KN:02"BSI$6KU,PG.;Z8G1=O86G$^+_W?OK( MN!>'XME$6("L,^2QGT3W<9^?\'C %:W[9[NE2URHN7#H/G# 6.$OW]I"S75# MY,$!2;(/DT][%Z">?7[+M_E5<]WEV_NJN6YH? EM?=5<>/EVOFJNNWP;7S77 MC:TNH7TOK#L='7IZ=NDMWZ17S75#P9NJX!N&FG(2NO&JN?!:P\QUEVY#H>BR MFW+PA@&GO7ONHONAQT9Q]. GRCKC3-7J,&3 5-EOU$U<]V0>'! DNS#NM/, M/;JQ@(H'!TR5_;:A 6=(/#@@2?9AX6GFK3OE<>KY(0OX8-*J*.:# M^\ 39MXC\_K]^-X+DOS[A*=ID%^P4]23!^UOJ.X#!R#ZA@(/#H #TCD (W#[ M1N .>OZ@AZSR9 $#";* @019P$""+& @018PD" +&$B0!0R[)8LSHO9708Y. M)K4U^2V+EG3].?K0N[R9#O/MSD_YVV3D]?F[,/H6>Z.#X\IE%+[-6@,=_98] M>LR&W$ON8ZY+IZ :>E#/,*2!!N7H%/3BKJFW&Q"3(D.<-M1(D2%MM$Z::18D M2SKT4B,U5[J8P*[5(O:!3K%:T 425.@""2IT@005ND"""ET@084ND*!"%TCL MG"X.CYIE3XSQ??YON7VWC=^!*JB"ZD]_!^VL?15SBI9V/G-]MW< MV[C3[SB'I6OSO%8YJ<%I'Y8NF+\1 _:CZ,BPW35=[NS#TLET:C.@?5BZ? 0V MWB8*7ZK-SG8(+Y0V6MDMPY+5S966DD[C3V]ILU6TG;;<.M(;+S2_9N59H#3 M.BQ=8AH;;WVV5^5N/%A'NGJ-DE)&D6EN)KMI^ O-J1^6[ML,?;Z)';&?J"<9 M!C3W)'=4&.#4X-_=S\:3:K_"D-+>S=1[*HDQ>]_H^O.GYY"WZJ]_9P\\3OV^ M%[SU G\0OLM(9+W#Q1\HNFO2-7L-LWD&23&).2^R$A-UY#YQ] MX3QD8L1^UJ1,/,:_]X/[C &O?N'_WOOI(^->'(J?DVD-4F%B=(8\]I/H/N[S M$QX/Q @SI-;X0XO%/!GQ?A80"QX/69;;G;'VK/N7X/,I#U,>BR]8_O_1B"7I M8\!G&8'&3C_R&,MNY_!7_=@^F0N8_KW:_M M_+\#]G?W[.:/]P=VM?KZ29Q.SR]OSJ^R 9B8C1AF,K\C,=LG@\N_3>_>M0[K M?GC 'P3\:YK_U4))J;XH*+:]3%).CH\^'U^??_Q3S(Q=G9_V+D^[%]W. M3;=WR6YZK/-G[_/ES37[='7^5[?W^?KB'_'0I][5S?F9X/3GXW$9MISC"R0N M%^&YB3Z;9S$I/]]?V9Y@I^<7F;U\VKW\^/Z@>I#__*ES=C;]>8:[)[VKL_.K M_/O)',;?O!607'0^79^_FWYXP9)NBNE,L>KGT&1<'XM.OF4G"F!"O=Y\/=%H M3[^9UPF3)YW7,ZKOYY\Q& 9;\EG>H;%Y6%]P;%S= 'C^Q-,)USF0,MZ2U^MD MM[\]Z=W<]/[,*A(NJWR^?*@?4VW,[_#(;>=)-V!P?I?[0)Q ^EZ2DM#^K<7:M/6RPM7]D3E, M+\X_W#QG_N]3=*ZR(=8'!Z^C?6W#,9WQOU<\]?Q@_/G3G1\=A4B%YX MC>T9P:);<"V'9?Y"7.2QG/?.K:A6/H>^.)*,/U^G0H:2U??ZIS6686^^C&L^ MR*SW*G]&N[ M;J\RM.K15@-YL]I+EL:NFWL7+WT7+%#UFWD8*-ZEH_$(:0_#LG>ML#S&15A' M.9 MS@QKJRY7TM^,)7>J6UVST>(FK\D"%GA;*O*VW-59=657R$V49D4L?^*F!'"[ F[5@V6)^0)!(+@S0VDC M/SUM@#?1K5(=V+#35++3]FR5/5V<>JK3/G&#E"F@I<"Y;8?Z9HT3WF8:9WP2 MK+F;G01_.G%@N20BOVU U_$LE9\]8-W^%EW5]:7=]J1C^>U($]<=5ZY/;B,K M<'6GW?<7C Q;@I&QX6TR&A)97.]>HY5V\@&':5<.V5;=7J+1A%E=4OTVW3=Y4[-8J\O*&*&LH M7#1L6ZZ+>X8J/:*U1W[A/8EUFF&0W^3ZQ/HJMF6WUJA']N)\5='3^D!H:CQ> M'P3K1MUEHN--WX%N==?7K5)/]&_V?*1?&0NZ1_^?]O-Z]: MQS?MECA';1;X4C_&J1F6N'V@&Z(5VZW)Q_.-0H#2,9QVI(WM=AO7$' -0950 MG%$G:@68"GA(,U4W>' -8Z-7>!0LCZD]OAU>_C%\/)-\)^D;M M;*M6=4T*W.D#77N-;L; C0YN%:F1TB,!'M(C 1XB(ZWM.7&7M!<6W[_H:9AYQIFV MS93H'T!+QTNY_;7M9T=L&2M0VEV'_MJTI;]D7^$?K;49NFIOB &Z:JLJ_>BJ MK< CI$,T> F5W8;C3MILVD2;?;[N0 _N5 ^>G(+ANV3X4Y?IO,9,WEO:) !H M]Y,6^(P[.;-Q$^>CDZO9OLDKKQ.5#]$O>3LWH>UJS:JO4KG#++:@BJ&^O"&0 M?[#RKI.9@;#2V9%6[4!*CY ^.Z)?\JI=6%VKCG[)Z)>\#8;9U8;B@B7]U5AR MJS;LUMX:)B-AKT3"7O[2>?7+M%^@7K&QRB#@(-3<\"*F?![1;+!?[,%"Q5W%8MU_! M=577CW;[DX[IMR-5W-HP)1.)>D0E6-D,E&V/!'A(CP1X2(]$ QY4ZL6U.30, MWD:D>*/FI36GMDK4U"2NJ'Z=;)N\J=CV"OYFQ:O[;7O/N3)]]G#)PR5?YK", MAL$2/3Y;#O95VHT5:LZO/%M5M+0^ )H:CM<'070+UO$61:5=WW/M8_0*1J]@ M'=3OCKI3UAI;Z$>J77!( 2QQ\T W1"NVO842P>@53!7OK'-[37)6#&X@J*.2 MU(O"&76<5H"I@(ORSEKH%;SET@/H%;SGD)UE-U" 0$GH'!=- MGI4$KH)>P1J'RVW+;:]@XZ/L@#J/:'W'$;V"M8DVU2VG;FH'4LV@7!8A<]OH M%:P%P([C& HD'4MP-SJYU71Q 0 7 %0)@BD?PB3!"HHC 1[2(P$>(B/E[T0N)W+/__:,22]#'@,P$2FP^?!5:RKPKG^R_\ M:Q2+\WWPS7M,#C)2?X@W_8I[NP73(/*CT[M=V_M\!^[M[=O-'UG*R^OK) MRC@]O[PYO\H&8&(V8IC)_([$;)\.[?YM>O>N=5CWPP/F!?X@?'\0\*]I_E>K M1GBJLQ$>VUX>[C_Z?'Q]_O%/,3-V=7[:NSSM7G0[-]W>);OILY^N+?\1#GWI7-^=G[.BWS\?32P%B*0M"6+:P9'Z?F^C/(UB92&08 MLM/SB\R;<]J]_/C^0)AIV<^?.F=GTY]GN#N6E?S[6>D1D%QT/EV?OYM^6,$W M,]>.ZCC#:6Q['4\^G$VIUUNO)UOUZ3?STCR=Y^N9/?WSSQ@,@V$P P:3Z%1& M=U/Q1;U4>^?9!O-.E42S83D1$:=*:1ATF-^.^-LMM)A7'00S6LROP]!G#6+7 MZ0B_I1 NU,TB8#:Y[[C6,3;G^Z)S[ ()&3@*IC:<%89;Z$=-9JRNC-;*E9G62^$/7 M:M;LU?Z8;![;;CCE6-7&BOEB9#DE_3U8AJ%UJU65V@.8+M]WP]"*;;5KSZXS M+B=$N3KU;CBV3AUWXO79=R1B[35>%I3EBY0F%"_AYF:=(=8Z'A24XQ'*Y,DI MDY=;DZ]^^92;DR3=OOJ6ZUK?#8@J:P1@,[6=')WR&N3VY>8WH\BCK@^LINY; M( @$@2#>G9J].R6&D.J+XP7UET,*=!_9>@B)[M(5YO$"T:50OG50C#FA=*NT M0_L.R@1F 3)T;=4"RC4B>-I!2<> VE%MS^IFY7A+>"(4D03-H%XGZ+G.Q%4* M7NT6TL6,08MMQ6'=_DY=-7:LZS8UZQVB,!'A(CP1X2(]$ QZ\NK951&%R,#&] M@$)>EBT(!+,L-N AC[-+M^$M\VZ'?N@G:5:[Z8$S_GW$PX0G,RE9O#GS9+3&8JQK!PE>LJN6G1Z?/7+LGA1V?0K M@C$FS2\.NU;#-C5O1S,H;:ON;.$6N!)0TGF_[B8%RW8EUS331A(T@[IB6[5Z MV^S<#LT@1?:5;HA6ZEO(8E=IAYKU^LULYLU4,K*OZ,LRQ;NQ)$8"/*1'H@$/ MKK C^TI5^ /+:8"'M),U0T>O+JVG'VUTL5>N['X&J?X_L6KGL2?V?K]7N+K M5YO7"R1Y"QW4>B.>!57# ?/#?C3DK!)$2?)&CV9J&^1O.)9M-U<8FNK5N:UF ME+G(Q=M0K&S+;:U_^7JIFC!1^BKN*NF,AK*F!M8L8\T*%ZK)>3U@=;0U$B- &S+?%D"/^3'X>5)P)Y%0S-%JHK06!>E1U2,Z*R59_-2 M[MPT)V^\@FCJ3QC_./8IC#^/0T:3S].$N_&//]+M)IB3 0WHD MP$-Z),!#9*07C/_GL4[761S9$M^_&/V:>:8^'4ABS.JPON PLKK(/7_B:;9B MYC+&VZ) _F#LCU-GGX M%KGB(TZ5TC UB/]6Q-]NE1'_3L)&,7_PH_LD>&0Q'T5QRF^WL0D PG(0?N09 MZ,SY=1CJS/-S(JPQ[WM)NH:?#.I&KJ0_ V:35)\7\7U1ELX"";GBJ><' MTTK48BG;)_GISHN'7O]Q2G07R^QFGT(O]:/0VV"U\TE0:U"^YH-,3ZU0ZUMI M567@UIF7XYULGK_OHH G7L#7WCV0X75E^(6PXTWODZ2@Y,8;8-,I"$SSA,TU MC:>?D]MM)3BS])D [,Q/^F*S^N&].&Z<7$VKID2AUB8P/1PZ)Z=@^"X9?AK% MXI#MI3R3^JR19R^]X[%)&&C](IHUS07$,];&GM]-ZY1ZVU6I"*HE(*Z%59J0 MK/"P\CVP#6J3V+95:RA9DVJ;7'%MK[#IR(H- <5EUZUZ;85WX:H7 MEZ7E7\L)#]-Z9.OYUW27KC"/)4;77KA6/]T\$R->[![V>W[@^AA'21;$CK[Z MJ18U=E]<\9HI&PO'>9ZG(:PTQY$P,MG$1^H .%:UMF;JHEH R'ZE[PFGAE5O MK-EO=]'(+QYSB*)('9Z*;;7M-5/.EDZ1GDU>_?,J/)R2C"7NL-B![ MP+G=5%O?Z8S*LP1P0^'+?=>%H+D2WD.7JZ:#\E@V*H5(9F/RI%*^"NDZ=/-V6[!'_>^M7Q M:E:](2%8L4E#2L1K6U_=B -E)DJ)C(BH"OLD"5 M(H+[%X?%S-J%3,@*QF^^2H@$)0TAXTJ ;OH!1L>2$TJKMG>C8]M5O9W25;V+ MQ_.Y<5^L^#WIY$1\?RA;]'';(P$>TB/1@$?BVT4!GDL+WRN"+D6FDQ@)\) > M"?"0'HD&/'AU:5UKQ:[N_>YT7I4O" 2W+#;@(8^SF]3A+?-NAW[H)VE6&NR! M,_Y]Q,.$)S-YG@3O5&\S*[UF5;/S^(LC&\44VVJZ2C)%=M;*!KRK6ZU5"HRL MIA8)LGB[Y5FL1DOE,ANHSK(GP5FEL A9J2&@M<1KL&W+TEJXZ/C31W#1444> M+Q!=2A<=%Z9+)FL< LAKQ3T'#'=!9/ZMYC36N)V^T:I4>26:"+X+\%6X2; / MV:A7JU((;AY(4D5VS!,.QVEO>5$ ??]$2N8I2EH7T">!_@J^6KTW/"R$YT>' MYEXMA(4^H#=+SM-JU$3:?Q.%8C;CHK/]JU^61?C*ICL2C KNL>C ^I>'U[\H M[%JMY^V3R\];B:OCFD%I6[6VJ5#2*22Q"Z3KEKOAID7ZH&)05\2NKJ^9]J-; MBH]FD&Z2U8<,/LJ(5MPU$[QUVZ%FO7Z%S>S4=_KZ12+=_F6B&?!UG# _+ ?#3FK!%&2O-&B=^8FB23N*MVUS6)) M=VB[O!ZUWA2\KZ %=;YW*Q^L#1":)O M&==FG:$HOG;'3E;(G# M&]5U4%U'!1XO$%W9'HS)IBR5!UO(OXN6Q'W06'!%-:A4VXYF#6T%C1>"MKMF M;I?60D [YWY?,I)5,)77# I9@9J*2:76V%I6RE4P5!K>-_I(0AHDP-.3U MI-5&%F!K+#R4U.79HU03(.W2"9 O)3D2%WV*=\])C 1X2(\$>$B/!'A(CP1X M2(\$>$B/!'B(C)0;_V*TWVXZ)Q?G^<"_G77_$M^?\C#EL?A=_MU)[^P?\>4? M-W]>'/]_4$L#!!0 ( / X?U(VTW\-2@0 #X2 0 =V)A+3(P,C$P M,S,Q+GAS9,U76V_;-A1^+]#_P.EI R91LN$$%N(4[=P, 9*L2-UM;P$M'3O$ M*%(CJ5S^_0XIR98O<6VG6^<74SSG._S.A8?DV;NG0I 'T(8K.0J2* X(R$SE M7,Y'065"9C+.@W?G;]^<_1"&9'QQ>4-"VT]);<@@!D@O;@7AZ?D0\5%GKJ/)$GB*.G"-#!GC^3,0DKZ MM)]05$Q(DB:GZ6! /EV3C\Q8T)),> %=J"J?-9_?6_)C]A/QH+&2$H2 9W+! M)9,99X)\;AG_3"YE%I'W0I!;!S-(TX!^@#QJK#Z9/#79/13L[1M",%[2I!)- M5L4H<(%HXO TU2)2>DYSJZE]+H&B4HA:H'D6=*!?QVU@,!%.8A; &3-3#VHE M&)YD&,9)V$\ZN,ND8IMZM^--8'M!9V MM W/MKN, N=RLN$RQGO.6+DU$4ZP'BAFK>;3RL*%TL489JP2R*Z2?U=,\!F' MW&OAQBA VA6=50W+]!SL#2O E"R#_;.*U;LM>!B/A/YY??79%W9P[@"$^%KG M1:FT)77)7ZG,[\0=.7-?89OJT$V%20_]C]!80.0FY9?KA-!7$VDKZ"@BB_+; MFXAY:;.X0;@LAINB(G!Y 9(E_;:5TVJ++RV#G\NM]]. D M;&V6%(0U[
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end